

AUTHOR INDEX

Page references to clinical nephrology meetings abstracts in journal number 4 are preceded by 4:A.

Articles under the rubric *Of Nephrology and Nephrologists* are referred to by journal number, a colon, and page numbers.

- Aamodt, K., 4:A2, 4:A9
 Abdalla, A. H., 631
 Abe, K., 843
 Ábráham, Gy., 4:A3, 4:A5
 Abu-Aisha, H., 866
 Ackrill, P., 593
 Adams, N. D., 4:A3, 4:A5
 Agodoa, L. Y., 720
 Agraharkar, M., 4:A3, 4:A5
 Aguilera, A., 569
 Akhtar, M., 115
 Akmal, M., 223
 Albalade, M., 392
 Alcázar, R., 239
 Alexiewicz, J. M., 233
 Al-Hawas, F., 631
 Al-Khader, A. A., 631
 Alkhunaizi, A. M., 936
 Allen, A. C., 285
 Al-Momen, A., 866
 Alpern, R. J., 291
 Al-Sulaiman, M. H., 631
 Al-Tuwaijri, A., 866
 Al-Wakeel, J., 866
 Amini, M., 277
 Ancarani, E., 277
 Anderson, L., 739
 Andreoli, S. P., 817
 Aparicio, M., 285
 Appel, L. J., 720
 Apple, F. S., 399
 Aronoff, G. R., 907
 Arrigo, G., 27
 Askepidis, N., 4:A2, 4:A19
 Assmann, K. J. M., 4:A3, 4:A16
 Atkinson, R., 560
 Audrain, M. A. P., 125
 Avecillas, J. F., 4:A4, 4A:11
 Averbukh, J., 230
 Avram, M. M., 4:A1, 4:A5
 Ayoub, E. M., 355
 Ayus, J. C., 4:A4, 4:A14

 Baddoura, F. K., 4:A3, 4:A16
 Badran, N., 4:A2, 4:A16
 Bailey, T. C., 428
 Bakris, G. L., 803
 Balfe, J. W., 136
 Baliga, R., 465
 Baluarte, H. J., 4:A1, 4:A6

 Bansal, V. K., 193
 Baragetti, I., 490
 Baranger, T., 125
 Bárány, P., 565
 Bargman, J. M., 620
 Barkeling, B., 691
 Barnes, R., 739
 Baronti, R., 4:A1, 4:A6
 Barré, P., 214
 Barrett, B. J., 214
 Barri, Y. M., 773
 Barrientos, A., 541
 Bartlett, S. T., 739
 Bastacky, S. I., 334
 Bastani, B., 947
 Battle, D., 4:A2, 4:A20
 Bays, H., 907
 Bazzi, C., 27
 Beaver, S. K., 851
 Becker, B., 4:A1, 4:A7
 Becker, G., 912
 Bellovich, K., 461
 Beltrame, A., 27
 Bender, F. H., 685
 Bereczki, C., 4:A3, 4:A5
 Bergström, J., 565
 Berlyne, G. M., 4:A1, 4:A10
 Bertani, T., 254
 Besarab, A., 223
 Best, J., 54
 Beto, J. A., 193
 Bianchi, G., 490
 Blanco, M., 4:A1, 4:A5
 Blau, N., 36
 Boehmer, J. P., 280
 Boeschoten, E. W., 584
 Bojti, T., 4:A2, 4:A15
 Bolin, P., Jr., 624
 Bonventre, J. V., 66, 793
 Bordenave, K., 4:A2, 4:A20
 Borochovit, D., 334
 Bouhaddi, M., 746
 Bradley-Guidry, C., 897
 Breborowicz, A., 404
 Brenes, L., 136
 Brennan, D. C., 428
 Bresson, C., 746
 Breyer, J. A., 167, 678
 Brezsyak, W., 549
 Briceno, L. F., 136

 Brier, M. E., 907
 Briggs, W. A., 4:A3, 4:A12, 4:A17
 Brody, R. I., 514
 Brown, E. A., 4:A2, 4:A13
 Brown, W. W., 368
 Budde, K., 871
 Buller, G. K., 959
 Bumgardner, G. L., 419
 Burdick, J. F., 4:A3, 4:A17
 Burgess, E., 4:A3, 4:A9
 Burke, S. K., 66, 4:A1, 4:A6
 Burshell, A., 4:A2, 4A:11
 Butani, L., 4:A1, 4:A6

 Campbell, E., 942
 Canessa, M., 45
 Caprioli, R., 4:A1, 4:A6
 Caramelo, C., 392
 Carney, D., 4:A2, 4:A16
 Carreño, V., 392
 Carter, D., 4:A2, 4:A14
 Casado, S., 392
 Cattran, D. C., 200
 Ceska, M., 871
 Chalopin, J. M., 746
 Chan, R., 4:A1, 4:A4, 4:A10, 4:A11
 Chang, J.-G., 769
 Chang, M.-H., 188
 Chapmar, A., 936
 Charytan, C., 4:A2, 4:A18
 Chawla, H., 514
 Chayen, D., 230
 Chen, C.-H., 188
 Chen, W., 4:A3, 4:A7
 Chen, Y. S., 4:A3, 4:A7
 Chertow, G. M., 66
 Choi, M., 4:A3, 4:A12
 Chugh, S., 4:A3, 4:A7
 Cioni, L., 4:A1, 4:A6
 Cisterne, J.-M., 96
 Clive, D. M., 627
 Cohn, M., 230
 Collins, J. F., 456
 Colosio, V., 254
 Combe, C., 285
 Conneen, S., 4:A2, 4:A20
 Coomer, R. W., 4:A1, 4:A7, 678
 Copley, J., 4:A2, 4A:11
 Corna, D., 254
 Coroneos, E., 132

- Cosio, F. G., 419
 Covic, A. C., 593
 Cowley, B. D., Jr., 265, 435
 Coxon, V., 207
 Crook, E. D., 4:A3, 4:A19
 Cruz, D. N., 759
 Curtis, J. J., 608
 Cutler, R. E., 897

 Daboczi, A., 4:A4, 4:A10
 D'Agati, V., 119
 Dahlmeier, B. A., 399
 Dai, Z., 4:A3, 4:A16
 D'Amico, G., 27
 Danatal, J., 125
 Danpure, C. J., 36
 Darragh, T. M., 754
 Dash, T., 445
 Davies, E. A., 419
 Dekker, F. W., 584
 De la Torre, M., 239
 Dell'Antonio, G., 490
 Deminière, C., 285
 Demko, T. M., 280
 Depner, T. A., 658
 De Sequera, P., 392
 Detwiler, R. K., 624
 Dheenan, S., 4:A1,
 Diamond, J. R., 280
 DiBenedetto, A., 881
 Di Francesco, G., 4:A1, 4:A8
 Di Iorio, B., 4:A1, 4:A8
 Dillon, M. A., 4:A1, 4:A6
 Distant, D. A., 881
 Donadelli, R., 254
 Donadio, J., 817
 Dotson, L., 106
 Doyle, G. D., 942
 Dressler, R., 119
 DuBose, T. D., Jr., 793
 Dumler, F., 685
 Dumoulin, G., 746
 Dunagan, W. C., 428
 Dunn, S. R., 72
 Durand, D., 96

 Eiam-Ong, S., 4:A4, 4:A8
 Eknoyan, G., 6:xxxix
 Elkhmmas, E. A., 419
 Ellison, D. H., 959
 Emancipator, S. N., 817
 Eqbal, A., 334
 Esnault, V. L. M., 125
 Evans, D., 739

 Farrell, J., 947
 Favilla, G., 4:A1, 4:A6
 Feehally, J., 285
 Fehmi, H., 4:A2, 4:A20
 Feldman, C., 4:A2, 4:A12
 Ferguson, R. M., 419
 Feriozzi, S., 277
 Fernvik, E., 78
 Fervenza, F., 273
 Figueroa, J., 4:A2, 4A:11
 Filangeri, J., 4:A2, 4:A18
 Filho, J. C. D., 565
 Fine, A., 103, 214
 Fine, B., 4:A1, 4:A9
 Finelli, A., 620
 Finger, M., 4:A1, 4A:11
 First, M. R., 303
 Fischer, F.-P., 246
 Fish, A., 4:A4, 4:A20
 Fishbane, S., 319
 Flanigan, M. J., 383
 Foda, H., 449
 Fogo, A., 806, 966
 Földes, K., 4:A4, 4:A14
 Fong, I., 763
 Forero, N., 4:A2, 4:A16
 Fotiadis, C., 4:A1, 4:A7
 Fournier, V., 746
 Frankenfield, D., 851
 Fraser, I., 912
 Frederick, P. R., 851
 Freedman, B. I., 729
 Friedman, E. A., 549, 881
 Fryer, P., 36
 Fujii, T., 733

 Gabuzda, G. M., 72
 Gallo, G., 514
 Garlick, P., 712
 Gassman, J. J., 888
 Gattone, V. H., II, 265, 435
 Ger, Y.-C., 345
 Gertner, R., 514
 Glassock, R. J., 633, 720, 817
 Goldberg, D. I., 66, 4:A1, 4:A6
 Goldfarb, D. S., 514
 Goldsmith, D. J. A., 593
 Goldstein, M. B., 214
 Goligorsky, M. S., 712
 Gottlieb, R. H., 362
 Graber, M., 449
 Grande, J. P., 817
 Grantham, J. J., 435
 Graves, G. S., 773
 Greco, B. A., 167
 Green, A., 273
 Greenberg, A., 334
 Grim, C., 720
 Groff, J. A., 280
 Grossman, E. B., 362
 Grubb, B., 4:A1, 4:A8

 Guella, A., 115

 Haegerstrand, A., 78
 Halevy, A., 230
 Hall, W. D., 720
 Halperin, M. L., 136
 Halpern, Z., 230
 Hammerman, M. R., 793
 Handa, S. P., 214
 Hara, N., 345
 Hare, I., 533
 Hargrove, G., 4:A3, 4:A9
 Hart, J., 739
 Hartman, K., 739
 Hass, M., 829
 Hedrick, C., 355
 Helgerson, S. D., 851
 Henrich, W. L., 4:A1, 4:A8
 Henry, M. L., 419
 Hernandez, B., 4:A2, 4:A14
 Herrero, J. A., 541
 Hewitson, T., 912
 Hickman, M., 4:A1, 4:A9
 Hilgers, K. F., 376
 Hill, S., 503
 Hirose, H., 86
 Ho, K. K. L., 699
 Hodgson, C., 4:A2, 4:A18
 Hoeft, P., 399
 Hoehn-Saric, E., 739
 Hoffmann, E. O., 4:A4, 4:A16
 Holley, J. L., 685
 Hong, J. H., 881
 Hoppe, B., 36
 Horberger, J., 4:A2, 4:A12
 Horn, R. G., 806
 Hory, B., 746
 Hsu, C. H., 641
 Huang, T.-P., 769
 Huraib, S., 866
 Hussain, S. T., 4:A4, 4:A20
 Husserl, F., 4:A2, 4A:11
 Hutchinson, F. N., 651
 Hylander, B., 691

 Ifudu, O., 549
 Igarashi, M., 526
 Ilamathi, E., 4:A1, 4A:11
 Inenaga, T., 733
 Ing, T. S., 288
 Inoue, T., 733
 Isoda, K., 86
 Itoyama, S., 86

 Jacobson, E. J., 4:A2, 4:A9
 Jacobson, S. H., 78
 Jaekels, J., 739
 Jager, K. J., 584
 Járay, J., 4:A4, 4:A10, 4:A14,
 4:A15
 Javit, D. J., 4:A4, 4A:11
 Jenci, Z., 4:A2, 4:A15

- Jenkins, P. G., 4:A1, 4:A10
 Jennings, P. R., 36
 Jenson, B. M., 576
 Jindal, K. K., 214
 Johnson, J. P., 334
 Johnson, L. B., 739
 Johnson, M., 763
 Johnson, R. J., 147
 Jones, B., 553
 Jones, K., 897
 Jones, W. J., 651
 Jordan, W., 947
 Joseph, A., 4:A1, 4:A10
 Julian, B. A., 608
- Kais, H., 230
 Kaiser, B., 4:A1, 4:A6
 Kakuk, Gy., 4:A2, 4:A15
 Kamel, K. S., 136
 Kammer, G. M., 729
 Kamran, A., 4:A1, 4:A10
 Kaneta, S., 435
 Kao, K. J., 355
 Kaplan, R. M., 888
 Kapoian, T., 479
 Karón, J., 404
 Karp, H., 368
 Kasuno, K., 931
 Katalinic, A., 871
 Katayama, H., 4:A4, 4:A20
 Kathuria, P., 106
 Katona, É., 4:A2, 4:A15
 Katsinas, C., 4:A2, 4:A19
 Kawamura, S., 345
 Kaysen, G. A., 658
 Keilarri, T., 4:A2, 4:A20
 Keystone, J., 620
 Khairullah, Q. T., 383
 Kharasch, E., 4:A1, 4:A12
 Kim, Y., 4:A4, 4:A20
 Kimura, G., 733
 Kindos, P., 4:A1, 4:A10
 Kirk, K. A., 720
 Kirsch, M., 4:A1, 4:A11
 Kjellstrand, C. M., 214, 669
 Klassen, D. K., 739
 Kletke, P. R., 781
 Knight, D. F., 368
 Knochel, J. P., 773
 Knoll, G. A., 608
 Kobayashi, M., 526
 Kohan, D. E., 2
 Kolecki, R. S., 72
 Kollár, L., 4:A3, 4:A14
 Kon, V., 817
 Konieczny, T., 4:A3, 4:A16
 Kooh, S. W., 136
 Kovács, T., 4:A3, 4:A14
 Kovithavongs, C., 669
 Koyama, A., 526
 Kozak, M., 280
- Krediet, R. T., 584
 Krieger, J. N., 207
 Kronmal, R. A., 207
 Kuhlmann, U., 246
 Kumar, A., 514
 Kuo, P. C., 739
 Kurtzman, N. A., 1
 Kürzdörfer, M., 871
 Kusek, J. W., 720
 Kushner, H., 45
 Kuwahara, T., 931
- Lafayette, R. A., 273, 445
 Lai, K. B., 699
 Lai, K. N., 91, 699
 Lakkis, F. G., 4:A3, 4:A16
 Lam, C. W. K., 699
 Langenfeld, M. R. W., 376
 Lasseur, C., 285
 Lasuncion, M. A., 569
 Latif, S., 461
 Laurel, M., 763
 Lavie, R. H., 4:A4, 4:A11
 Lázár, N., 4:A4, 4:A14
 Lazarus, J. M., 66
 LeBeau, S. O., 410
 Lee, J. Y., 608
 Lee, P., 54
 Lee, P.-I., 188
 Lee, S. M. K., 953
 Leehey, D. J., 288
 Le Mao, G., 96
 Lennert, T., 777
 Leumann, E., 36
 Leung, C. B., 91
 Leung, J. C. K., 699
 Levin, A., 214, 533
 Levison, S., 45
 Levy, E., 453
 Lewis, M., 533
 Li, P. K. T., 91
 Lim, V. S., 383
 Lin, G., 230
 Lindberg, J., 4:A2, 4:A11, 4:A18
 Lippi, A., 4:A1, 4:A6
 Llach, F., 496
 Lochhead, K., 4:A1, 4:A12
 López, D. G., 392
 Lopez, T., 4:A1, 4:A8
 Lu, M.-Y., 188
 Luft, F. C., 777
 Lundahl, J., 78
 Lundin, A. P., 4:A1, 4:A10
 Luzzana, E., 254
- McCann, L., 4:A2, 4:A12
 McCarthy, J. T., 576
 McClellan, W. M., 368, 851
 McClendon, E., 549
 McCrary, R., 4:A1, 4:A9
 McDonald, B. R., 615
 Macey, L. J., 549
- McLaughlin, K., 553
 McMullan, M., 851
 McNurlan, M., 712
 Mactier, R., 553
 Maesaka, J. K., 319
 Maffi, R., 254
 Majkowski, N. L., 706
 Mandin, H., 214
 Manske, C. L., 601
 Marcen, R., 569
 Markell, M. S., 881
 Marquez-Julio, A., 4:A2, 4:A11
 Marriott, E., 392
 Marshall, S., 119
 Martin, P., 541
 Martin, S. J., 125
 Martinez, I., 496
 Martinez, J. R., 435
 Martis, L., 404
 Masaki, K., 345
 Massengill, S. F., 355
 Massry, S. G., 223, 720
 Mathew, S., 4:A3, 4:A12
 Mathur, V. S., 754
 Matsumura, O., 86
 Matthew, J. J., 549
 Mauer, M., 4:A4, 4:A20
 Maursky, V., 881
 Mayers, J. D., 549
 Mazumdar, C., 4:A1, 4:A10
 Mehrotra, R., 106
 Mehta, R. L., 793
 Memon, N., 866
 Mendelssohn, D. C., 533
 Mendley, S. R., 706
 Merkus, M. P., 584
 Mettang, T., 246
 Michelis, M. F., 4:A1, 4:A4, 4:A10, 4:A11
 Miles, A.-M. V., 881
 Mirsa, M., 4:A2, 4:A13
 Mitarai, T., 86
 Mitch, W. E., 5:xlvi
 Mitchell, H. C., 897
 Mittman, N., 4:A1, 4:A5
 Modesto, A., 96
 Mohácsi, Cs. G., 4:A3, 4:A5
 Molitoris, B. A., 793
 Molnar, M., 4:A3, 4:A13
 Monk, R. D., 362
 Montenegro, J., 496
 Moore, B., 4:A1, 4:A11
 Mora, S., 490
 Moreau, A., 125
 Morgan, J., 214
 Moritz, M., 4:A4, 4:A14
 Morris, M., 456
 Morrissey, E. C., 615
 Mortiboy, P., 533
 Mousa, D. H., 631
 Muda, A. O., 277

- Muessel, M. J., 265
Muirhead, N., 214
Murakawa, M., 86
Murarta, G. H., 4:A2, 4:A20
Murphy, B., 54
Myers, J., 4:A2, 4:A16
Myrthil, G., 966
- Nagai, R., 200
Nagai, Y., 345
Nagao, S., 435
Nagy, J., 4:A3, 4:A13, 4:A14
Nakamura, K., 345
Nakamura, S., 733
Nakanishi, K., 345
Naquin, J., 4:A2, 4A:11
Narula, S., 4:A3, 4:A16
Necosad Study Group, 584
Negri, M., 230
Nemes, B., 4:A4, 4:A14
Neu, L. T., 947
Neuhaus, T., 36
Neumayer, H.-H., 871
Nguyen, N. U., 746
Nicholls, K., 912
Nishida, Y., 919
Nolph, K. D., 106
Nuchikat, P., 4:A3, 4:A18
- Obialo, C. I., 4:A2, 4:A14
Oda, H., 919
Oksman, F., 96
Oliver, B., 4:A3, 4:A19
Olivero, J., 132
Olorenshaw, I. M., 729
Olson, J. L., 754
O'Neal, D., 54
Ootaka, T., 843
Oreopoulos, 404
Ortega, H., 569
Ortiz, A., 392
Ortuño, J., 569
Otti, T., 947
- Páll, D., 4:A2, 4:A15
Paller, M. S., 793
Palmarini, D., 4:A1, 4:A6
Parfrey, P. S., 214
Parker, M. G., 445
Passlick-Deetjen, J., 246
Patterson, J., 103
Peces, R., 239
Pedagogos, E., 912
Perazella, M. A., 759, 959
Peresleni, T., 712
Perner, F., 4:A4, 4:A10, 4:A14, 4:A15
Pesavento, T. E., 419
Petrini, C., 27
Podder, H., 4:A4, 4:A10, 4:A14, 4:A15
Polgár, P., 4:A2, 4:A15
- Polinsky, M., 4:A1, 4:A6
Polner, K., 4:A2, 4:A21
Poon, P., 699
Popov, D., 449
Porter, E., 533
Porter, J. R., 4:A4, 4:A16
Porteus, C., 553
Portolés, J., 541
Preese, L. M., 399
Provenzano, R., 461
- Querques, M., 4:A1, 4:A8
- Rabetoy, G. M., 615
Randall, O. S., 720
Rao, T. K. S., 549
Rasul, I., 620
Reaveley, D. A., 4:A2, 4:A13
Regnard, J., 746
Remuzzi, G., 254
Reydel, C., 549
Richards, R. J., 4:A4, 4:A16
Richardson, R. M. A., 214
Rindi, P., 4:A1, 4:A6
Rivera, M., 569
Rizza, V., 27
Rocco, M. V., 888
Rodela, H., 404
Rodrigo, J., 541
Ronco, P., 115
Ross, J., 4:A2, 4A:11
Rössner, S., 691
Rostaing, L., 96
Royal, H. D., 560
Rubens, D. J., 362
Rumsby, G., 36
Rupp, J. C., 265
Rutecki, G., 4:A3, 4:A18
- Saad, T. F., 4:A2, 4:A16
Sabatini, S., 4:A4, 4:A8
Saffarian, N., 461
Sághy, L., 4:A3, 4:A5
Saint-Hillier, Y., 746
Saito, T., 843
Sakhaee, K., 291
Saleem, S., 4:A3, 4:A16
Salem, M. M., 4:A2, 4:A17, 862
Samaniego, M., 4:A3, 4:A17
Sanchez, M. I., 136
Sang, G. L. S., 669
Sansom, S. C., 971
Santoro, S. A., 560
Saracho, R., 496
Sárszegi, Z., 4:A3, 4:A14
Sato, H., 843
Saxena, R., 4:A3, 4:A18
Schaedler, R. W., 72
Scheel, P. J., Jr., 4:A3, 4:A12
Schenk, U., 246
Scherbenske, J., 793
Schiff, M., 685
- Schlueter, W., 4:A2, 4:A20
Schmidt, R. J., 685
Schmieder, R. E., 376
Schnitzler, M. A., 428
Schoch, L., 947
Schubiger, G., 36
Schulman, G., 678, 720
Schweitzer, E. J., 739
Schwenk, M., 4:A2, 4:A18
Seed, M., 4:A2, 4:A13
Sehgal, A. R., 410
Sekine, S., 86
Senzaki, H., 931
Shah, S. V., 465
Shappell, S. B., 966
Sharkey, S. W., 399
Sherman, R., 223
Sherman, R. A., 479
Sherrard, D. J., 207
Shoemaker, J. D., 947
Shyr, U., 678
Shyr, Y., 4:A1, 4:A7
Sica, D., 897
Siegel, N. J., 793
Simenhoff, M. L., 72
Skeate, R., 399
Slatopolsky, E. A., 66, 4:A1, 4:A6
Sleasman, J. W., 355
Sloan, R., 907
Slowik, M., 4:A2, 4:A18
Smith, J., 4:A1, 4:A9
Smith, L., 456
Smith, R. D., 897
Smith, S., 4:A2, 4A:11
Smogorzewski, M., 233
Soldati, L., 490
Soma, J., 843
Sommer, B. G., 881
Sonkodi, S., 4:A3, 4:A5
Sótonyi, P., 4:A4, 4:A10, 4:A15
Spaia, S., 4:A2, 4:A19
Spinowitz, B. S., 4:A2, 4:A18
Spitznagel, E. L., 428
Spray, B. J., 729
Squillace, D. P., 576
Sreedhara, R., 4:A1, 4:A5
Stalker, D. J., 907
Stenzel, K. H., 66
Stevens, P., 584
Stevenson, F. T., 658
Stockand, J. D., 971
Stokes, M. B., 514
Striker, G. E., 793
Sugawara, A., 931
Suh, H., 712
Sumrani, N., 881
Superdock, K. R., 72
Surgrue, T., 549
Svec, F., 4:A4, 4:A16
Szeto, C. C., 91, 699
Takahasi, H., 435

- Tamura, H., 86
 Tan, D., 392
 Tanaka, A., 931
 Tanaka, M., 345
 Tankersley, M. R., 608
 Tarrng, D.-C., 769
 Tastet, M., 4:A2, 4:A18
 Tato, A., 569
 Taylor, R., 4:A2, 4:A3, 4:A17, 4:A19
 Tecuanhuey, L., 4:A2, 4:A16
 Teele, R. L., 456
 Teng, R.-J., 188
 Terracciano, V., 4:A1, 4:A8
 Teruel, J. L., 569
 Testa, A., 125
 Testa, D., 254
 Theodoridis, M., 4:A2, 4:A19
 Thomas, S., 246
 Thomas, W., 601
 Thompson-Bell, S., 897
 Thompson, L., 207
 Thylén, P., 78
 Tokushima, H., 86
 Torday, Cs., 4:A3, 4:A5
 Török, K., 4:A3, 4:A14
 Torralbo, A., 541
 Tóth, K., 4:A3, 4:A14
 Toto, R. D., 897
 Touboura, M., 4:A2, 4:A19
 Truong, L., 132
 Tsau, Y.-K., 188
 Tsouchnikas, I., 4:A2, 4:A19
 Tsuzuki, D., 931
 Túri, S., 4:A3, 4:A5
 Tuttle, A. B., 729
 Tzamaloukas, A. H., 4:A2, 4:A20
 Ueda, N., 465
 Ueda, S., 931
 Ulan, R., 669
 Urrea, J. M., 239
 Uzu, T., 733
 Valderrábano, F., 6:xxxii
 Vats, A., 4:A4, 4:A20
 Vayonas, G., 4:A2, 4:A19
 Vázquez, A., 392
 Vella, J. P., 942
 Venkatesan, J., 4:A1, 4:A8
 Venning, M. C., 593
 Vezzoli, G., 490
 Videen, J., 897
 Vogel, F. E., 4:A4, 4:A11
 Voss, E., 399
 Wadhwa, N., 712
 Wagner, L., 4:A3, 4:A14
 Waiser, J., 871
 Waite, N. M., 763
 Waldo, F. B., 817
 Walker, A., 4:A2, 4:A11
 Walker, P. D., 465
 Walser, M., 503
 Walshe, J. J., 942
 Wang, S.-R., 888
 Wang, Y., 601
 Warnock, D. G., 793
 Watterson, M. K., 624
 Webster, N., 763
 Weinberg, E. P., 362
 Weir, M. R., 739, 800
 Weissgarten, J., 230
 Welshman, I., 907
 Whittmann, I., 4:A3, 4:A13
 Williams, A. W., 576
 Wilson, C. H., 729
 Wilson, R. F., 601
 Windus, D. W., 560
 Wolf, G., 153
 Wombolt, D., 66
 Woodward, R. S., 428
 Wortley, P., 207
 Wyatt, R. J., 817
 Yager, H., 4:A3, 4:A7
 Yamaguchi, S., 345
 Yamaguchi, T., 435
 Yamakido, M., 919
 Yamase, H., 4:A3, 4:A5
 Yen, T. S. B., 754
 Yoon, S., 739
 Yorgin, P., 136
 Yorioka, N., 919
 Youngner, S. J., 410
 Yu, A. S. L., 453
 Yu, A. W. Y., 91
 Yu, W., 4:A2, 4:A20
 Yutani, C., 733
 Zager, R., 4:A1, 4:A12
 Zarrabi, M. H., 449
 Zent, R., 200
 Zerbi, S., 490
 Zheng, Y. P., 4:A3, 4:A7
 Zilahi, Zs., 4:A2, 4:A15
 Ziyadeh, F. N., 153
 Zoja, C., 254
 Zrinyi, M., 4:A2, 4:A21

SUBJECT INDEX

Page references to clinical nephrology meetings abstracts in journal number 4 are preceded by 4:A.

Articles under the rubric *Of Nephrology and Nephrologists* are referred to by journal number, a colon, and the page number(s).

- Ab(s), *see* Antibodies
 Abdominal adiposity, role of insulin resistance and, in dyslipidemia of CRF, 54-65
 ABPM, *see* Ambulatory blood pressure monitoring
 Abstracts of sixth annual spring clinical nephrology meetings (April 17-20,1997), 4:A1-A21
 ACE, *see* Angiotensin-converting enzyme genotype; Angiotensin-converting enzyme inhibitor(s)
 Acid-base balance concept
 chronic metabolic acidosis and, 292-294
 see also pH
 Acid signaling in chronic metabolic acidosis, 298-299
 Acidosis
 tubular, classification of, 136-146
 see also Metabolic acidosis
 Acquired immunodeficiency syndrome, *see* Human immunodeficiency virus-associated nephropathy; Human immunodeficiency virus infection
 ACTH (corticotropin; adrenocorticotrophic hormone) in CRF, effects of ketoconazole plus low-dose prednisone on, 503-513
 Acute allograft rejection, IL-8 expression following renal transplantation and, 871-880
 Acute peritonitis on CAPD, NO pathway and amino acids in, 712-719
 Acute-phase response, and albumin concentrations in ESRD patients on HD, 658-668
 Acute renal failure (ARF)

- due to postinfectious GN during pregnancy, 273-279
 - see also* Acute renal failure, management and outcome of; Oxidants in toxic ARF
- Acute renal failure (ARF), management and outcome of, 793-799
 - adjunctive agents in, 794-795
 - dialysis for, *see* Dialysis for ARF
 - future directions in, 798-799
 - nephrotoxin avoidance in, 795-796
 - nutritional support in, 795
 - role of hemodynamic monitoring in, 794
- Acute respiratory distress in heparin-induced thrombocytopenia and thrombosis, 449-452
- Acute tubular necrosis, acute allograft rejection and, and IL-8 expression following renal transplantation, 871-880
- Adaptations to chronic renal ischemia, 170
- Adenocarcinoma due to chronic lithium ingestion, 4:A3, 4:A5
- Adenoma due to chronic lithium ingestion, 4:A3, 4:A5
- Adenosine diphosphate (ADP), and effects of aspirin or ticlopidine on platelet deposition on PTFE graft fistulas, 563
- Adhesion molecules
 - glomerulointerstitial interaction of, in IgAN and MPGN, 843-850
 - role of, in monocyte and granulocyte adherence to human saphenous vein endothelial cells during HD, 78-85
- Adiposity, abdominal, role of insulin resistance and, in dyslipidemia of CRF, 54-65
- Adjunctive drugs in ARF management, 794-795
- Administrative issues related to management of IgAN renal biopsy data, 823-824
- ADP (adenosine diphosphate), and effects of aspirin or ticlopidine on platelet deposition on PTFE graft fistulas, 563
- ADPKD, *see* Autosomal dominant polycystic kidney disease
- Adrenocorticotrophic hormone (ACTH; corticotropin) in CRF, effects of ketoconazole plus low-dose prednisone on, 503-513
- Advanced secondary hyperparathyroidism (HPT), calcitriol effects on, 4:A1, 4:A6-A7
- Adverse effects
 - of chronic lisinopril and fosinopril therapy, 901
 - of Na ramping in HD, 669-678
 - see also* specific therapeutic modalities
- African American(s), *see* Race and ethnicity
- African-American Study of Kidney Disease and Hypertension, 720-728
- Age
 - of ANCA-associated vasculitis patients, 97
 - of arteriolar sclerosis patients, 914
 - and attitudes toward financial incentives for kidney donation, 412, 414
 - of children with biliary atresia, 189
 - of CRF and/or ESRD patients, *see* Age of CRF and/or ESRD patients
 - of FSGS patients with NS in CAE, 336
 - of hypertensive patients, *see* Age of hypertensive patients
 - of ICGN patients with HIV and HCV infections, 516
 - of IgAN patients, 528, 530, 833
 - of IMN patients, 201
 - of membranous nephropathy patients, 116
 - of myocardial infarction patients with renal artery stenosis, 734
 - and nephrotic syndrome patients with hematuria and renal insufficiency, 806-810
 - of NIDDM patients, 908
 - of preeclamptic nephropathy patients, 347
 - of renal physicians, 783, 785, 789
 - of renal transplant recipients, *see* Age of renal transplant recipients
 - SLC, albuminuria and, 47
 - of SLE patients, 357
 - and vasectomy as risk factor for urolithiasis, 208, 209
 - see also* Children; Elderly, the; High-school students; Young African Americans
- Age of CRF and/or ESRD patients
 - on dialysis, reproductive and gynecologic issues and, 686;
 - see also* Age of CRF and/or ESRD patients on CAPD and/or HD
 - and effects of ketoconazole plus low-dose prednisone on CRF progression, 505
 - with lupus nephritis, 731
 - in MDRD study, 891, 894
- Age of CRF and/or ESRD patients on CAPD and/or HD
 - ABPM and, 594, 679
 - and dialysate Na effects on hypertension, 384
 - with dyslipidemic CRF, 55
 - and effects of exit-site povidone-iodine ointment on infections, 764
 - as factor influencing Ab response to HBV vaccine, 239-245
 - with HIVAN, 550
 - with HPT, 863, 864
 - with hyperphosphatemic CRF, 68
 - on in-center HD, 854, 856
 - on nifedipine therapy, 234
 - positive for HCV, 610, 611
 - and preservation of residual renal function, 578
 - and quality of life 3 months after start of chronic HD and/or PD, 586, 589
 - and resistance to rHuEPO, 566
 - starting dialysis, early death and, 217, 219
- Age of hypertensive patients
 - endogenous EPO and, 377
 - on HD, dialysate Na effects, 384
 - of hospitalized hypertensive and diabetic patients, 370
 - and racial differences in effects of antihypertensive therapy, 723
 - renal allograft survival and, 420, 423
- Age of renal transplant recipients
 - diabetic, atherosclerotic vascular complications and, 602
 - hypertensive, renal allograft survival and, 420, 423
 - of inner-city recipients, 882
 - of long-term recipients, high-bone turnover and HPT and, 747, 749, 750
 - positive for HCV, 610, 611
- AGT (alanine:glyoxylate aminotransferase), deficiency of, in PHI, 36-44
- AIDS (acquired immunodeficiency syndrome), *see* Human immunodeficiency virus-associated nephropathy; Human immunodeficiency virus infection
- Air embolism, paradoxical cerebral, due to central venous catheter, 453-455

- Al (aluminum)
 in ESRD with HPT, 863, 864
see also Serum aluminum in CRF and/or ESRD
- Alanine:glyoxylate aminotransferase (AGT), deficiency of, in PH1, 36-44
- Alanine transaminase (ALT; serum glutamate pyruvate transaminase; SGPT)
 in ARF due to postinfectious GN during pregnancy, 274
 in children with biliary atresia, 189
 in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446
 in ICGN with HIV and HCV infections, 516
- Albumin
 in ascitic patients, 394, 395
 in ESRD with HPT, 863, 864; *see also* Albumin in CRF and/or ESRD patients on CAPD and/or HD
 postural hemodilution in nephrotic edema and, 628
 serum, *see* Serum albumin
see also Albuminuria; Hypoalbuminemia
- Albumin in CRF and/or ESRD patients on CAPD and/or HD, 57, 505
 and Ab response to HBV vaccine, 240
 before and after CAPD, 695, 696
 concentration of, 658-668
 starting dialysis, 216
- Albuminuria
 SLC associated with insulin resistance and, race and, 45-53
see also Proteinuria
- Aldosterone
 ACE inhibitor effects on, 4:A2, 4:A20-A21
 postural hemodilution in nephrotic edema and, 628
- Alkali, bone, release of, in metabolic acidosis, 297-298
- Alkaline phosphatase (ALP)
 in ARF due to postinfectious GN during pregnancy, 274
 in children with biliary atresia, 189
 following parathyroidectomy for secondary HPT in HD patients, 760
- Alkaline urine, PCO₂ in, in tubular acidosis, 138-139
- Alkalosis, hypokalemic metabolic, with hypomagnesuric hypermagnesemia and severe hypocalciuria, 106-114
- Alleles in HD patients having received HBV vaccine, 242
- Allograft, *see* Renal transplantation
- ALP, *see* Alkaline phosphatase
- Alpha (α)-interferon for fibrillary GN associated with HCV infection, 132-135
- ALT, *see* Alanine transaminase
- Aluminum, *see* Al
- AMA (American Medical Association) Physician Masterfile, 781-782
- Ambulatory blood pressure monitoring (ABPM)
 of hypertensive patients, 377, 386
see also Ambulatory blood pressure monitoring in CAPD patients
- Ambulatory blood pressure monitoring (ABPM) in CAPD patients, 678-684
 and in HD patients and in renal transplant recipients, 593-600
- Amenorrhea in ESRD patients on dialysis, 685-690
- American Medical Association (AMA) Physician Masterfile and, 781-782
- Amino acid(s)
 NO pathway and, in acute peritonitis on CAPD, 712-719
 urinary excretion of, in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446
- Aminoaciduria in nonacidotic proximal tubulopathy with hypercalciuria, 493
- Aminotransferase
 deficiency in alanine:glyoxylate, in PH1, 36-44
see also Alanine transaminase; Aspartate transaminase
- Amlodipine, short-term effects of, on GFR in hypertensive nephrosclerosis, 720-728
- Ammonia, *see* NH₃
- Ammonium, *see* NH₄
- Amoxicillin, proton-pump inhibitor and, in eradication of *H pylori* in dialysis patients with ESRD, 86-90
- Amputation in diabetic renal transplant candidates, 601-607
- Amyloid A, serum, and albumin concentrations in ESRD patients on HD, 658-668
- Amyloidosis, primary, syncope with, 4:A3, 4:A18
- Anatomic correlates of IRD, 168-169
- ANCAs, *see* Antineutrophil cytoplasmic antibodies following renal transplantation; Perinuclear antineutrophil cytoplasmic antibodies
- Androgens, effects of, on serum lipid levels, in chronic HD patients, 569-575
- Anemia
 in children with biliary atresia, 189
 therapy of, *see* Recombinant human erythropoietin
- Angiographic studies of atherosclerotic RAS, 172-173
- Angioplasty, *see* Percutaneous transluminal renal angioplasty
- Angiotensin II (AII)
 in diabetic nephropathy, 153-163
 lisinopril as inhibitor of, in membranous nephropathy, 254-264
- Angiotensin-converting enzyme (ACE) genotype, IgAN prognosis and, 819
- Angiotensin-converting enzyme (ACE) inhibitor(s)
 antiproteinuric effects of, 801, 803-805
 as AII antagonist in diabetic nephropathy, 153-163
 Ca channel blockers and, 801
 effects of, on K and aldosterone, 4:A2, 4:A20-A21
 enalapril as, *see* Enalapril
 fosinopril as, chronic therapy of chronic renal insufficiency with, in older hypertensive patients, racial differences in renal response to, 897-906
 for hospitalized hypertensive and diabetic patients, 368-375
 in hypertensive nephrosclerosis, short-term effects of, on GFR, 720-728
 lisinopril as, *see* Lisinopril
- Anions, urinary excretion of, in tubular acidosis, 140
- ANP (atrial natriuretic peptide), postural hemodilution in nephrotic edema and, 628
- Antibiotics
 effects of, on degradation of Cr in CRF, 72-77
 for *Xanthomonas maltophilia*, 93
see also specific antibiotics
- Antibodies (Abs)
 antineutrophil cytoplasmic, *see* Antineutrophil cytoplasmic antibodies following renal transplantation
 antiphospholipid, in pediatric SLE, 355-361

- antipodocyte and anti-brush border, in familial idiopathic membranous nephropathy, 115-118
- factors influencing response of, to HBV vaccine in HD patients, 239-245
- Anti-brush border antibodies in familial idiopathic membranous nephropathy, 115-118
- Antigen(s)
- cancer antigen 125 and dialysate cell population in stable CAPD patients, peritoneal transport parameters and, 699-705
 - see also* HLAs
- Antihypertensive therapy
- effectiveness of, 4:A2, 4:A17
 - effects of, on GFR, race and, 720-728
 - see also specific antihypertensive agents; for example:* Angiotensin-converting enzyme inhibitor(s); Ca channel blocker(s)
- Antineutrophil cytoplasmic antibodies (ANCA) following renal transplantation
- IgA, recurrence of IgAN with, 125-131
 - outcome of vasculitis associated with, 96-102
 - see also* Perinuclear antineutrophil cytoplasmic antibodies
- Antinuclear factor in membranous nephropathy, 116
- Anti-oxygen (O_2) free radicals, tea polyphenol, for CRF, 4:A3, 4:A7
- Antiphospholipid antibodies (aPLs) in pediatric SLE, 355-361
- Antipodocyte antibodies in familial idiopathic membranous nephropathy, 115-118
- Antiproteinuric effects of Ca channel blockers, influence of dietary NaCl on, 800-805
- Apheresis, pseudopulmonary embolism in heparin-induced thrombocytopenia and, 449-452
- aPLs (antiphospholipid antibodies) in pediatric SLE, 355-361
- Apolipoproteins
- in CRF, 57
 - nandrolone decanoate effects on concentrations of, in chronic HD patients, 569-575
- Apoptosis in PKD, paclitaxel effects on, 435-444
- Appetite of ESRD patients on CAPD and after renal transplantation, changes in, 691-698
- ARF, *see* Acute renal failure
- Arginine in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446
- L-arginine, depletion of, in acute peritonitis on CAPD, 712-719
- Arteriolar hyalinosis in proteinuric GN, 30, 31
- Arteriolar sclerosis, myofibroblasts and, in diabetic nephropathy, 912-918
- Arteriovenous access, *see* Peripheral arteriovenous versus central venous vascular access
- Arteriovenous (AV) disequilibrium in peripheral AV versus CVV access
- cardiopulmonary recirculation, dialysis delivery and, 483-484
 - defined, 488
- Arteriovenous (AV) fistula
- percutaneous mechanical thrombectomy in salvage of, 4:A1, 4:A9
 - pulse oxymetry of O_2 saturation in upper extremity with, before and after HD, 230-232
- Arthritis, rheumatoid, in relatives of lupus nephritis patients, 731
- Ascites in children with biliary atresia, 189
- Ascitic fluid reinfusion, concentrated, in cirrhosis, 392-398
- Aspartate transaminase (AST; SGOT)
- in ARF due to postinfectious GN during pregnancy, 274
 - in HCV infections, *see* Aspartate transaminase in HCV infection
 - in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446
- Aspartate transaminase (AST; SGOT) in HCV infection
- in ESRD patients, 610, 611
 - in ICGN with HIV and HCV infections, 516
- Aspirin, effects of ticlopidine and, on platelet deposition on PTFE graft fistulas, 560-564
- Associated conditions, *see* Comorbidity in CRF and/or ESRD patients
- AST, *see* Aspartate transaminase
- Atenolol, short-term effects of, on GFR in hypertensive nephrosclerosis, 720-728
- Atheroembolism, cholesterol, FSGS with NS in, 334-344
- Atherosclerotic renal artery stenosis, *see* Renal artery stenosis
- Atherosclerotic vascular complications in diabetic renal transplant recipients, 601-607
- Atresia, biliary, elevated HGF in children with, 188-192
- Atrial natriuretic peptide (ANP), postural hemodilution in nephrotic edema and, 628
- Attitudes of patients toward financial incentives for kidney donation, 410-418
- AII, *see* Angiotensin II
- Autosomal dominant liver disease, portal hypertension and bleeding esophageal varices with, 4:A3, 4:A18
- Autosomal dominant nonacidotic proximal tubulopathy, 490-495
- Autosomal dominant polycystic kidney disease (ADPKD)
- portal hypertension and bleeding esophageal varices with, 4:A3, 4:A18
 - sex and effects of gonadal hormones on progression of, 265-272
- AV, *see* entries beginning with term: Arteriovenous
- Azotemia in ADPKD, 265-272
- B cells, effects of nifedipine discontinuation on cytosolic Ca and proliferation of, in CRF patients on HD, 233-238
- Bacterial toxins, renal disorders due to, ETs in, 14
- Beneficial effects of Na ramping in HD, 669-678
- Berger's disease, *see* IgA nephropathy
- BF, *see* Blood flow, vascular access; Renal blood flow
- Bicarbonate, *see* HCO_3
- Bicarbonaturia in renal tubular acidosis, 137-138, 141, 144
- Bilateral renal artery stenosis (RAS) in IRD, 173; *see also* Ischemic renal disease
- Bilateral renal vein thrombosis (RVT), proteinuria secondary to, systemic thrombolytic therapy of, 615-619
- Biliary atresia, elevated HGF in children with, 188-192
- Bilirubin in ARF due to postinfectious GN during pregnancy, 274
- Biochemistry
- following parathyroidectomy for secondary HPT in HD patients, 759-762
 - of mesangial cell contraction, 973-974

- see also specific biochemical data*
- Biocompatibility of glucose polymer-containing PDFs, 246-253
- Bioelectrical impedance analysis of nephrotic edema, 627-630
- Biology of ETs, *see* Endothelin biology
- Biopsy, *see* Renal biopsy
- Birth control, sexual activity and, in ESRD women on dialysis, 687
- Bleeding esophageal varices, portal hypertension and, due to ADPKD, 4:A2, 4:A18
- Blood alterations in IgA nephropathy, 4:A3, 4:A14
- Blood flow (BF), vascular access
relationship of recirculation to, 223-229
see also Blood flow in peripheral AV versus CVV access
- Blood flow (BF) in peripheral AV versus CVV access, 484-487
dialyzer and, 486-487
see also Regional blood flow model in peripheral AV versus CVV access
- Blood pressure (BP)
ambulatory, *see* Ambulatory blood pressure monitoring of ascitic patients, 394
dietary salt, proteinuria and, 800-803, 805
epidemiological data of high-school students', 4:A2, 4:A15
in ESRD, *see* Blood pressure in CRF and/or ESRD with IgAN, 530
in IMN, 201, 202
of membranous nephropathy patients on lisinopril therapy, 257
Na ramping effects on, in HD, 673
in preeclampsia, 347
see also Hypertension; Hypotension
- Blood pressure (BP) in CRF and/or ESRD, 578
effects of multidisciplinary predialysis interventions on, 536
in hyperphosphatemic CRF, 68
quality of life and, 891
rHuEPO effects on, in predialysis patients, 543-545
- Blood urea, and vascular access BF, 224
- Blood urea nitrogen, *see* BUN
- BMI, *see* Body mass index
- Body mass index (BMI)
of CRF and/or ESRD patients, 55, 567, 695, 696
of hypertensive patients, 377, 420, 423, 723
of NIDDM patients, 908
of renal transplant recipients, 420, 423, 747, 749
SLC, albuminuria and, 47, 49, 50
- Body weight (BW)
of ADPKD subjects, 267, 268
of CRF and/or ESRD patients, 68, 543, 695, 696
of hypertensive patients, 377, 420
of membranous nephropathy patients on lisinopril therapy, 257
Na ramping in HD and gain in, 671-673
sex and, and nephrosclerosis, 4:A4, 4:A16
SLC, albuminuria and, 47
- Bone alkali, release of, in chronic metabolic acidosis, 297-298
- Bone density
with reduced renal function, 4:A3, 4:A9
rHuEPO effects on, 4:A2, 4:A11-A12
- Bone disease
hyperparathyroid, calcitriol therapy of, 646-647
low-turnover, calcitonin effects in dialysis patients with, 4:A2, 4:A19
nonacidotic proximal tubulopathy and, 493
- Bone metabolism with reduced renal function, 4:A3, 4:A9
- Bone turnover
high-, HPT and, in normocalcemic long-term renal transplant recipients, 746-753
low-, bone disease with, calcitonin effects in dialysis patients with, 4:A2, 4:A19
- Bowel
severe hyperphosphatemia following phosphate administration for preparation of, in renal failure patients, 103-105
see also Short bowel syndrome and entries beginning with term: Intestinal
- BP, *see* Blood pressure
- Brequinar sodium, 310
- BUN (blood urea nitrogen)
in hospitalized hypertensive and diabetic patients, 370
in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446
serum, in ARF due to postinfectious GN during pregnancy, 274
- BW, *see* Body weight
- Ca (calcium)
in CRF and/or ESRD, *see* Ca in CRF and/or ESRD
dietary, *see* Dietary Ca
in glucose polymer-containing PDFs, 247
in hypokalemic metabolic alkalosis with hypomagnesuric hypermagnesemia and severe hypocalciuria, 108
hypophosphatemia, *see* Ca, hypophosphatemia and total, *see* Total Ca
see also Ca channel blocker(s); Calciuria; Hypercalcemia; Hypocalcemia and entries beginning with terms: Noncalcemic, Normocalcemic
- Ca (calcium), hypophosphatemia and
in multiple myeloma with hyperphosphaturia and hypophosphatemia, 446
P-enriched conventional Ca-containing dialysis solution for hypercalcemia and hypophosphatemia with HPT, 288-290
- Ca (calcium) channel blocker(s) (CCBs)
antiproteinuric effects of, influence of dietary NaCl on, 800-805
felodipine as, for hypertension with impaired cognitive function, MRI evidence of white matter, and multi-infarct disease, 4:A2, 4:A9
nifedipine as, effects of discontinuation of, on cytosolic Ca, and B cell proliferation in CRF patients on HD, 233-238
- Ca (calcium) in CRF and/or ESRD
cytosolic, effects of nifedipine discontinuation on B cell proliferation and, in CRF patients on HD, 233-238
dietary, *see* Dietary Ca for HPT in CRF and/or ESRD patients
effects of multidisciplinary predialysis interventions on, 536

- with HPT, 863, 864
- see also Ca and phosphate metabolism management in CRF and/or ESRD
- Ca (calcium) and phosphate metabolism management in CRF and/or ESRD, 641-649
 - Ca metabolism in ESRD, 642-644
 - Ca metabolism in normal subjects, 641-642
 - phosphate metabolism in ESRD, 644-645
 - proposed, 646
 - soft tissue calcification due to Ca and phosphate overload and, 645-646
 - therapy of secondary HPT and hyperparathyroid bone disease with calcitriol and, 646-647
- CaC₂O₄ (calcium oxalate) in PH1, 36-44
- CAD, see Coronary artery disease
- CAE (cholesterol atheroembolism), FSGS with NS in, 334-344
- Calcification, soft tissue, due to Ca and phosphate overload in ESRD, 645-646
- Calciphylaxis in Crohn's disease without ESRD, 773-776
- Calcitonin, effects of, in dialysis patients with low-turnover bone disease, 4:A2, 4:A19
- Calcitriol [1,25-dihydroxyvitamin D₃; 1,25-(OH)₂D₃]
 - effects of, on intestinal Ca absorption, 642
 - plasma, in nonacidotic proximal tubulopathy with hypercalciuria, 493
 - response to HBV vaccine and, 240
 - for secondary HPT, see Calcitriol for secondary HPT
 - serum, in long-term renal transplant recipients, 747, 749
- Calcitriol [1,25-dihydroxyvitamin D₃; 1,25-(OH)₂D₃] for secondary HPT
 - with bone disease, 646-647
 - with CRF, 496-502
 - pulse, for advanced secondary HPT patients on HD, 4:A1, 4:A6-A7
- Calcium, see Ca
- Calcium oxalate (CaC₂O₄) in PH1, 36-44
- Calciuria
 - hypercalciuria in nonacidotic proximal tubulopathy, 490-495
 - in nonacidotic proximal tubulopathy, 493
 - severe hypocalciuria with hypokalemic metabolic alkalosis and hypomagnesuric hypermagnesemia, 106-114
- Calculi, see Nephrolithiasis; Urolithiasis
- Cancer, see Multiple myeloma; Renal transplantation in patients with malignant disease
- Cancer antigen 125, dialysate cell population and, in stable CAPD patients, peritoneal transport parameters and, 699-705
- CAPD, see Continuous ambulatory peritoneal dialysis
- Capillary-mesangial biomechanical unit in GFR regulation, 972
- Carbon dioxide partial pressure (PCO₂) in alkaline urine in tubular acidosis, 138-139, 141
- Carbonic anhydrase II deficiency, HCMA and, 143-144
- Cardiac troponin I (cTnI) and cardiac troponin T (cTnT), serum, and prognosis of chronic HD patients, 399-403
- Cardiopulmonary recirculation in peripheral AV versus CVV access
 - AV disequilibrium, dialysis delivery and, 483-484
 - defined, 488
- Cardiovascular (CV) risk factors on dialysis for CRF and/or ESRD, 4:A2, 4:A13
- Cardiovascular (CV) system
 - rHuEPO effects on, in predialysis CRF patients, 541-548
 - see also Heart rate entries beginning with terms: Myocardial, Venovenous, Ventricular and elements: Arteri-, Card-, Vascu-
- Catalytic Fe (iron), cytochrome P-450 as source of, in myoglobinuric ARF, 471-472
- Catheters
 - infected, see Exit-site infections, catheter; Tunnel infections
 - recirculation and type of, 480, 483
 - see also Long-term vascular access for HD, catheters for; Venous catheters
- CCBs, see Ca channel blocker(s)
- Cell population, cancer antigen 125 and dialysate, in stable CAPD patients, peritoneal transport parameters and, 699-705
- Cell proliferation, excessive, glomerular diseases with ECM accumulation, fibrosis and, ETs in, 14-15
- Cellulose acetate dialyzers, preservation of residual renal function with PS and/or, in ESRD patients on CAPD, compared, 576-583
- Central venous catheters, paradoxical cerebral air embolism due to, 453-455
- Central venovenous (CVV) access, see Peripheral arteriovenous versus central venovenous vascular access
- Central venovenous (CVV) catheters, recirculation with, 483
- Cerebral air embolism, paradoxical, due to central venous catheter, 453-455
- Cerebrovascular accidents (CVAs) in diabetic renal transplant candidates, 601-607
- C4bp, PS and, 931-935
- CGN, see Crescentic glomerulonephritis
- Chemotherapy of tMF with light chain deposition disease, 942-946
- Children
 - with biliary atresia, elevated HGF in, 188-192
 - with SLE, aPLs in, 355-361
- Chloride, see Cl
- Cholesterol
 - in CRF, see Cholesterol in CRF
 - hypercholesterolemia, myocardial infarction, and renal artery stenosis, 734
 - total, in diabetic renal transplant candidates, 602
 - see also Lipids
- Cholesterol atheroembolism (CAE), FSGS with NS in, 334-344
- Cholesterol in CRF, 57
 - effects of RenaGel on, in hyperphosphatemic CRF, 66-71
- Chronic fosinopril and/or lisinopril therapy in older hypertensive patients with chronic renal insufficiency, racial differences in renal response to, 897-906
- Chronic glomerulopathy, CRF and, 505, 507
- Chronic hemodialysis (HD)
 - for ESRD, see Chronic hemodialysis for CRF and/or ESRD
 - nandrolone decanoate effects on serum Lp(a) concentrations in patients on, 569-575
 - serum cardiac troponin I and cardiac troponin T and prognosis of patients on, 399-403

- Chronic hemodialysis (HD) for CRF and/or ESRD
 enalapril-rHuEPO interaction in patients on, 4:A2, 4:A18
 quality of life 3 months after start of, 584-592
 rehabilitation of patients on, 4:A2, 4:A21
 withdrawal from, 4:A2, 4:A20
- Chronic interstitial nephritis, ESRD and, 653
- Chronic metabolic acidosis, 291-302
 acid-base balance concept and, 292-294
 defined, 291-292
 homeostatic response to, 294-300
 therapy of, 300
- Chronic pyelonephritis, ESRD and, 660
- Chronic renal failure (CRF)
 anemia of, *see* Recombinant human erythropoietin for CRF
 and/or ESRD patients on CAPD and/or HD
 anti-oxygen free radicals of tea polyphenols for, 4:A3, 4:A7
 creatinase activity induction in, 72-77
 diabetic, *see* Diabetic chronic renal failure and/or end-stage renal disease
 dialysis for, *see* Dialysis for CRF and/or ESRD
 dyslipidemia of, role of abdominal adiposity and insulin resistance in, 54-65
 ET-1 in, 16-17
 nutrition in, *see* Chronic renal failure, nutrition in
 progression of, and to, *see* Progression of (and to) CRF and/or ESRD
 RenaGel as noncalcemic phosphate binder for hyperphosphatemia in, 66-71
 secondary HPT with, dietary P and Ca in, 496-502
see also End-stage renal disease
- Chronic renal failure (CRF), nutrition in
 hypoalbuminemia and, 658-668
 MDRD study of quality of life in, 888-896
 metabolic acidosis influence on nutrition, 5:xlvi-xlviii
- Chronic renal insufficiency in the elderly
 with hypertension, chronic lisinopril and/or fosinopril therapy of, racial differences in renal response to, 897-906
- IMN and, 203
- Chronic renal ischemia, adaptations to, 170
- Chronic vascular disease/GGS in FSGS with NS, 339
- Cirrhosis, concentrated ascitic fluid reinfusions in, 392-398
- Citrate
 tubular absorption of, in chronic metabolic acidosis, 294-296
 urinary excretion of, in tubular acidosis, 140, 141
- Citrulline in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446
- CK-MB (creatinine kinase MB), and myocardial injury diagnosis in chronic HD patients, 399-403
- Cl (chloride)
 dietary Na, influence of, on antiproteinuric effects of Ca channel blockers, 800-805
 in glucose polymer-containing PDFs, 247
 in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446
 in hypokalemic metabolic alkalosis with hypomagnesuric hypermagnesemia and severe hypocalciuria, 108
 postural hemodilution in nephrotic edema and, 628
 serum, *see* Serum Cl
- Classification
 of FSGS with NS in CAE, 337-338
 histologic IgAN subclassification, 829-842
 of tubular acidosis, 136-146
- Clinical course
 of ICGN with HIV and HCV infections, 516
 of IgAN and MPGN, ICAM1, ICAM3, and LFA1 interstitial expression and, 846-847
 of relapsing NS, 967
see also entries beginning with term: Progression
- Clinical features and presentation
 of ANCA-associated vasculitis patients, 97
 of FSGS with NS in CAE, 336-337
 of ICGN with HCV and HIV infections, 515-516
 of IgAN, 528
 of IRD, 175-176
 of primary amyloidosis with syncope, 4:A3, 4:A18
see also Symptom(s) and specific conditions
- Clinical studies and trials of new immunosuppressive agent(s), 303-312
 of brequinar sodium, 310
 of costimulatory signals and fusion proteins, 311
 of CsA, 304-305
 of CsG, 305
 of 15-deoxyspergualin, 310-311
 of FK-506, 305-307
 of HLA-derived peptides, 311-312
 of leflunomide, 308
 of mizoribine, 308-309
 of mycophenolate mofetil, 309-310
 of rapamycin, 307
 of SKF-105685, 311
- Clinicopathologic correlations from IgAN database of Mayo Nephrology Collaborative Group, 820-821
- CMV (cytomegalovirus) infection, effects of, on renal allograft and patient survival, 428-434
- CO₂ (carbon dioxide)
 effects of P-enriched conventional Ca-containing dialysis solution on, 289
 partial pressure, in tubular acidosis, 138-139, 141
 total, ARF due to postinfectious nephritis in pregnancy, 274
- Cognitive function, felodipine for hypertension with MRI evidence of white matter, multi-infarct disease, and impaired, 4:A2, 4:A9
- Collagen, and effects of aspirin or ticlopidine on platelet deposition on PTFE graft fistulas, 563
- Collagen III in arteriolar sclerosis, 912-918
- Collagen mRNA (messenger ribonucleic acid), skin fibroblast, in IDDM nephropathy patients, 4:A4, 4:A20
- Collapsing glomerulopathy with IC deposits, HIV and HCV infections and, 519-520
- Collecting duct, inner medullary, fluid and electrolyte transport by, ET effects on, 8-10
- Communication, computerized, in vascular access management, 4:A2, 4:A18-A19
- Comorbidity in CRF and/or ESRD patients
 and quality of life 3 months after start of chronic HD and/or PD, 586, 588, 589
 starting dialysis, early death and, 214-222
see also specific conditions

- Compartmental volume loss during HD, 4:A1, 4:A11
- Complement, *see* C4bp; C1q nephropathy
- Computerized communication in vascular access management, 4:A2, 4:A18-A19
- Concentrated ascitic fluid reinfusion in cirrhosis, 392-398
- C1q nephropathy, relapsing NS, minimal change NS, FSGS and, 966-970
- Constrictive perinephritis (Page kidney), hypertension secondary, 620-623
- Continuous ambulatory peritoneal dialysis (CAPD)
- ABPM in patients on, *see* Ambulatory blood pressure monitoring in CAPD patients
 - for CRF and/or ESRD, *see* Continuous ambulatory peritoneal dialysis for CRF and/or ESRD
 - dialysate cell population and cancer antigen 125 in stable patients on, peritoneal transport parameters and, 699-705
 - peritonitis on, *see* Peritonitis on CAPD
- Continuous ambulatory peritoneal dialysis (CAPD) for CRF and/or ESRD
- Ca and phosphate metabolism in, *see* Ca and phosphate metabolism management in CRF and/or ESRD
 - changes in eating behavior on, and after renal transplantation, 691-698
 - HHD for patients trained in self-care, 4:A1, 4:A10
 - preservation of residual renal function with PS and/or cellulose acetate membrane dialyzers in, compared, 576-583
 - see also* Dialysis for CRF and/or ESRD
- Continuous renal replacement therapy (CRRT) for ARF, 796
- Conventional Ca (calcium)-containing dialysis solution, P-enriched, HD with, for hypercalcemia and hypophosphatemia with HPT, 288-290
- Coronary artery disease (CAD)
- in diabetic renal transplant candidates, 601-607
 - renal artery stenosis and, 733-738
- Cortical membranes, effects of K depletion on lipids and protein of, 4:A4, 4:A8-A9
- Cortical mitochondria, *see* Renal cortical mitochondria
- Corticosteroids
- effects of, on lymphocytes in primary GN, 4:A3, 4:A17
 - long-term therapy of HIVAN with, 624-626
 - see also specific corticosteroids*
- Corticotropin (ACTH; adrenocorticotrophic hormone) in CRF, effects of ketoconazole plus low-dose prednisone on, 503-513
- Cortisol in CRF, effects of ketoconazole plus low-dose prednisone on, 503-513
- Cost-effectiveness of anemia screening prior to starting rHuEPO therapy of ESRD patients, 651-657
- Costimulatory signals, fusion proteins and, in immunosuppression, 311
- Country of graduation of renal physicians, 783, 785, 787, 789
- Cr, *see* Creatinine and creatinine clearance
- C-reactive protein (CRP) in CRF and/or ESRD patients on HD
- albumin concentrations and, 658-668
 - as predictor of resistance to rHuEPO, 565-568
- Creatine kinase MB (CK-MB), and myocardial injury diagnosis in chronic HD patients, 399-403
- Creatininase, induction of activity of, in CRF, 72-77
- Creatinine (Cr) and creatinine (Cr) clearance
- in ascitic patients, 394
 - in CRF and/or ESRD, *see* Creatinine and creatinine clearance in CRF and/or ESRD
 - in hospitalized hypertensive and diabetic patients, 370
 - in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446
 - in hypokalemic metabolic alkalosis with hypomagnesuric hypermagnesemia and severe hypocalciuria, 108
 - in IgAN, 530
 - in long-term renal transplant recipients, high-bone turnover and HPT in, 747, 749
 - in membranous nephropathy, 116
 - in NIDDM, 908
 - plasma, in ascitic patients, 394
 - postural hemodilution in nephrotic edema and, 628
 - serum, *see* Serum creatinine
 - SLC, albuminuria and, 49
- Creatinine (Cr) and creatinine (Cr) clearance in CRF and/or ESRD
- before and after CAPD, 695
 - effects of antibiotics on degradation of, 72-77
 - effects of multidisciplinary predialysis interventions on, 536
 - in IMN, 202, 203
 - and rHuEPO therapy in predialysis patients, 543
 - with secondary HPT, 496
- Crescentic glomerulonephritis (CGN)
- IgAN and, 528
 - necrotizing, ANCA-associated vasculitis and, 96-102
- CRF, *see* Chronic renal failure
- Critical renal perfusion pressure, IRD and, 169
- Crohn's disease, calciphylaxis in, without ESRD, 773-776
- CRP, *see* C-reactive protein in CRF and/or ESRD patients on HD
- CRRT (continuous renal replacement therapy) for ARF, 796
- Cryoglobulinemia in ICGN patients with HIV and HCV infections, 516
- CsA, *see* Cyclosporin A
- CsG (cyclosporin G; OG37-325), 305
- cTnI (cardiac troponin I) and cTnT (cardiac troponin T), serum, and prognosis of chronic HD patients, 399-403
- Current supply of renal physicians, 782-784
- CV system, *see* Cardiovascular system
- CVAs (cerebrovascular accidents) in diabetic renal transplant candidates, 601-607
- CVV (venovenous) access, *see* Peripheral arteriovenous versus central venovenous vascular access
- Cyclosporin A (CsA)
- clinical trials and studies of, 304-305
 - see also* Nephrotoxicity of CsA
- Cyclosporin G (CsG; OG37-325), 325
- Cyst(s), tubular, due to lithium ingestion, 4:A3, 4:A5
- Cystic disease, *see* Autosomal dominant polycystic kidney disease; Autosomal dominant polycystic liver disease; Polycystic kidney disease, CRF and/or ESRD and; Progression of PKD
- Cystine in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446

- Cytochrome P-450, as source of catalytic Fe in myoglobinuric ARF, 471-472
- Cytokines
and hypoalbuminemia in ESRD patients on HD, 658-668
and Lp effects on mesangial cell proliferation, 919-930
- Cytomegalovirus (CMV) infection, effects of, on renal allograft and patient survival, 428-434
- Cytoplasmic antibodies, *see* Antineutrophil cytoplasmic antibodies following renal transplantation
- Cytosolic Ca, effects of nifedipine discontinuation on B cell proliferation and, in CRF patients on HD, 233-238
- Database development on IgAN biopsy, issues related to, 822-823
- DBP (diastolic blood pressure), *see* Blood pressure
- Death, *see* Mortality of HD patients
- Dehydrogenase, lactate, in ARF due to postinfectious GN during pregnancy, 274
- Dense deposit disease, IgAN and, 528
- Density of bones, *see* Bone density
- Dent's disease, nonacidotic proximal tubulopathy compared with, 493
- 15-Deoxyspergualin, 310-311
- Detection, *see* Diagnosis and detection
- Diabetes mellitus (DM)
in FSGS with NS in CAE, 336
myocardial infarction, renal artery stenosis and, 734
as risk factor for presence of atherosclerotic RAS in IRD, 173
see also Diabetic nephropathy; Renal transplantation in diabetic patients
- Diabetic chronic renal failure (CRF) and/or end-stage renal disease (ESRD), 412, 414
and ABPM monitoring in CAPD patients, 679
in chronic HD patients, residual renal function preservation using polysulfone dialyzers and, 581
and effects of ketoconazole and low-dose prednisone on CRF progression, 503-513
with HCV infection, 610, 611
in HD patients, early death prediction and, 217
with HPT, 863-864
with hyperphosphatemia, 68
hypoalbuminemia and, 658-668
in in-center HD patients, 854, 856
NIDDM-related, pharmacokinetics of oral glyburide in, 907-911
quality of life in, 586, 588
race and sex as risk factors for, 4:A3, 4:A19-A20
- Diabetic nephropathy
All in, 153-163
dialysate Na effects on hypertension in, 384
due to IDDM, collagen mRNA in skin fibroblasts, MMP-1, and tissue inhibitor of metalloproteinase-1 in, 4:A4, 4:A20
due to NIDDM, 4:A3, 4:A13-A14
early detection and management of hospitalized patients with, 368-375
effects of exit-site povidone-iodine ointment on infections in, 764
myofibroblasts and arteriolar sclerosis in, 912-918
and renal transplantation in inner-city residents, 883
see also Diabetic chronic renal failure and/or end-stage renal disease
- Diagnosis and detection
CK-MB and myocardial injury, in chronic HD patients, 399-403
differential FSGS, 148
early, of renal disease in hospitalized diabetic and hypertensive patients, 368-375
of IRD, 176-178
primary, *see* Primary disease
of relapsing NS, 967
see also Screening and specific conditions and techniques; for example: Renal biopsy
- Dialysate cell population, cancer antigen 125 and, in stable CAPD patients, peritoneal transport parameters and, 699-705
- Dialysate Na (sodium), effects of, on hypertension, 383-391
- Dialysis
for ARF, *see* Dialysis for ARF
calcitonin effects in low-turnover bone disease patients on, 4:A2, 4:A19
for CRF and/or ESRD, *see* Dialysis for CRF and/or ESRD
initiation of, in multidisciplinary predialysis interventions, 533-540
pseudopulmonary embolism in heparin-induced thrombocytopenia in patients on, 449-452
surgical revascularization of dialysis-dependent IRD, 180
see also Dialyzer(s); Hemodialysis; Peritoneal dialysis *entries beginning with terms:* Dialysate, Dialysis, Intradialytic
- Dialysis for ARF, 796-797
PD for ARF with HUS, pleural effusion complicating, 4:A1, 4:A6
urea measuring vascular access recirculation in, 4:A1, 4:A10-A11
- Dialysis for CRF and/or ESRD
amoxicillin and proto-pump inhibitor in eradication of *H pylori* in patients on, 86-90
Lp(a) and other cardiovascular risk factors on, 4:A2, 4:A13
with PS and/or cellulose acetate dialyzers, preservation of renal function with, compared, 576-583
women on, gynecologic and reproductive issues in, 685-690
see also Continuous ambulatory peritoneal dialysis for CRF and/or ESRD; Dialysis delivery in CRF and/or ESRD; Hemodialysis for CRF and/or ESRD; Peritoneal dialysis for CRF and/or ESRD
- Dialysis delivery
in ARF, 796
see also Dialysis delivery in CRF and/or ESRD
- Dialysis delivery in CRF and/or ESRD
adequacy of, in in-center HD (1993-1995), 851-861
hypoalbuminemia and, 658-668
suboptimal, in hospitalized ESRD patients, 4:A2, 4:A14-A15
see also Dialysis delivery with peripheral AV versus CVV access
- Dialysis delivery with peripheral AV versus CVV access, 487-488
AV disequilibrium, cardiopulmonary recirculation and, 483-484

- Dialysis fluids and solutions
conventional Ca-containing, enriched with P for hypercalcemia and hypophosphatemia with HPT, 288-290
see also Peritoneal dialysis fluids
- Dialyzer(s)
in ARF dialysis, 796-797
BF of, in peripheral AV versus CVV access, 486-487
PS and/or cellulose acetate, preservation of residual renal function with, in ESRD patients on CAPD, compared, 576-583
- Diastolic blood pressure, *see* Blood pressure
- Dietary Ca (calcium)
long-term renal transplant recipients' intake of, high-bone turnover and HPT in, 747, 750
see also Dietary Ca for HPT in CRF and/or ESRD patients
- Dietary Ca (calcium) for HPT in CRF and/or ESRD patients, 863
for secondary HPT, importance of dietary P and, 496-502
- Dietary NaCl (sodium chloride), influence of, on antiproteinuric effects of Ca channel blockers, 800-805
- Dietary P (phosphorus), importance of dietary Ca and, in secondary HPT with CRF, 496-502
- Dietary protein intake
by CRF patients, quality of life and, 891
effects of, on renal work, historical view of, 777-780
- Diethylene triamine pentacetic acid (DTPA), clearance of, in hypokalemic metabolic alkalosis with hypomagnesuric hypermagnesemia and severe hypocalciuria, 109
- Differential diagnosis of FSGS, 148
- Diffuse progressive glomerulonephritis (DPGN), IgAN and, 528, 530
- Diffuse proliferative lupus nephritis (DPLN), PS deficiency and, 931-935
- 1,25-Dihydroxyvitamin D₃, *see* Calcitriol
- Diphosphate, adenosine, and effects of aspirin or ticlopidine on platelet deposition on PTFE graft fistulas, 563
- Disequilibrium, *see* Arteriovenous disequilibrium in peripheral AV versus CVV access; Venovenous disequilibrium in peripheral AV versus CVV access
- Distal solute reabsorption, fractional, in hypokalemic metabolic alkalosis with hypomagnesuric hypermagnesemia and severe hypocalciuria, 106-114
- Diuresis
need to reduce, renal work concept and, 777-780
see also Urinary excretion
- DM, *see* Diabetes mellitus
- Donors
living, effects of education program for families of renal transplantation candidates on rates of, 739-745
opinion polls on ethical problems related to, 4:A4, 4:A10
patient attitudes toward financial incentives for kidney donation, 410-418
- Dose
corticosteroid, *see* Dose, corticosteroid
rHuEPO, resistance to rHuEPO and, 567
- Dose, corticosteroid
and effects on lymphocytes in primary GN, 4:A3, 4:A17
ketoconazole and low-dose prednisone effects on progression of CRF, 503-513
- DPGN (diffuse progressive glomerulonephritis), IgAN and, 528, 530
- DPLN (diffuse proliferative lupus nephritis), PS deficiency and, 931-935
- DTPA (diethylene triamine pentacetic acid), clearance of, in hypokalemic metabolic alkalosis with hypomagnesuric hypermagnesemia and severe hypocalciuria, 109
- Dual-lumen catheters, silicon, long-term vascular access for HD using, with guidewire replacement of catheters, 553-559
- Dysfunctional signaling pathways in mesangial cell regulation of GFR in renal disease, 976-977
- Dyslipidemia of CRF, role of abdominal adiposity and insulin resistance in, 54-65
- Eating behavior, changes in, of ESRD patients on CAPD and after renal transplantation, 691-698
- ECM, *see* Extracellular matrix
- Edema, nephrotic, postural hemodilution in, as cause of hemorrhage following renal biopsy, 627-630
- Education
patient, on multidisciplinary predialysis interventions, 533-540
program of, for families of renal transplantation candidates, effects of, on LD rates, 739-745
see also Educational status
- Educational status
and attitudes toward financial incentives for kidney donation, 412, 414
of CRF patients, quality of life and, 891
of inner-city renal transplant recipients, 882
and quality of life 3 months after start of chronic HD and/or PD, 586, 588
and vasectomy as risk factor for urolithiasis, 209
- Elderly, the
chronic renal insufficiency in, *see* Chronic renal insufficiency in the elderly
with IRD, SCr following renal artery angioplasty in, 4:A4, 4:A11
therapy of IMN in, 200-206
- Electrolytes, *see* Fluid and electrolytes
- Electrophoresis, sodium dodecyl sulphate-polyacrylamide gel, proteinuria in GN characterized with, 27-35
- Embolism, 449-455
FSGS with NS in cholesterol atheroembolism, 334-344
paradoxical cerebral air, due to central venous catheter, 453-455
pseudopulmonary, in heparin-induced thrombocytopenia and thrombosis, 449-452
- Employment status
of diabetic renal transplant candidates, 602
of HCV-positive ESRD patients, 610
and quality of life 3 months after start of chronic HD and/or PD, 588, 589
unemployment among inner-city renal transplant recipients, 881-887
- Enalapril
rHuEPO interaction with, in chronic HD patients, 4:A2, 4:A18
short-term effects of, on GFR in hypertensive nephrosclerosis, 720-728
- Encapsulating peritonitis, sclerosing, surgery of, 456-460
- Endogenous erythropoietin, *see* Erythropoietin

- Endothelial cells, human saphenous vein, serum factors inhibiting adherence of monocytes and granulocytes to, during HD, 78-85
- Endothelin (ET) biology, 2-26
 future directions in, 17
 general, 2-3
 in kidney, *see* Endothelin biology in kidney
 in glomerulus, 6-7
 in renal disorders, 12-17
 in renal resistance vessels, 4-6
 in renal tubule, 7-11
- Endothelin (ET) receptors, 3-5
 general biology of, 3
 in renal tubule, 8
 in renal vasculature, 4-5
- Endothelin-1 (ET-1)
 in hypertension, 15-17
 in preeclamptic nephropathy, 345-354
 see also Endothelin biology; Glomerular filtration rate, ET-1 and; Renal vasculature, ET-1 in
- Endotheliopathy, as continuum of HUS due to MMC therapy, 280-284
- End-stage renal disease (ESRD)
 Ca and phosphate metabolism management in, *see* Ca and phosphate metabolism management in CRF and/or ESRD
 calciophylaxis in Crohn's disease without, 773-776
 diabetic, *see* Diabetic chronic renal failure and/or end-stage renal disease
 dialysis for, *see* Dialysis for CRF and/or ESRD
 ET-1 in, 16-17
 following Li therapy, 4:A3, 4:A7
 with HCV infection, renal transplant effects on survival with, 608-614
 IRD and, 175
 multidisciplinary predialysis interventions for, 533-540
 and proteinuric GN, 32-33
 see also Chronic renal failure; Recombinant human erythropoietin for CRF and/or ESRD patients on CAPD and/or HD
- Entomophthoromycosis, systemic, severe hypertension secondary to, 620-623
- Enzymic phenotype, lack of relationship between genotype, severity of PH1 and, 36-44
- Epidemiological data
 on high-school students' BP and urine analysis, 4:A2, 4:A15
 see also Prevalence
- Epithelial cell proliferation in PKD, paclitaxel effects on, 435-444
- EPO, *see* Erythropoietin
- ERA-EDTA (European Renal Association-European Dialysis and Transplant Association) Registry, 6:xxxii
- Erythropoietin (EPO)
 in CAPD and HD patients, and renal transplant recipients, ABPM and, 594
 correlation between hypertension and, 376-382
 in ESRD 3 months after start of chronic HD, 586, 588
 see also Recombinant human erythropoietin
- Esophageal varices, bleeding, and portal hypertension due to ADPKD, 4:A3, 4:A18
- ESRD, *see* End-stage renal disease
- Essential hypertension, *see* Hypertension
- Estrogen replacement therapy for dialyzed ESRD women, 685-690
- ET, biology of, *see* Endothelin biology
- Ethical problems attached to donor issues, opinion polls on, 4:A4, 4:A10
- Ethnicity, *see* Race and ethnicity
- Etiology
 of IRD, 167-168
 see also specific conditions
- European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry, 6:xxxii
- Exit-site infections, catheter
 catheter removal and replacement for, 706-711
 exit-site povidone-iodine ointment in prevention of, 763-768
- Experimental therapies of ARF, 797
- Extracellular matrix (ECM)
 glomerular diseases due to fibrosis, excessive cell proliferation, and accumulation of, ETs in, 14-15
 lisinopril effects on, in membranous nephropathy, 254-264
- Extremity, upper, pulse oxymetry of O₂ saturation in, with AV fistula before and after HD, 230-232
- Faculty, future nephrology, 636-637
- Familial clustering of ESRD in African Americans with SLE, 729-732
- Familial idiopathic membranous nephropathy in identical twins, 115-118
- Familial Mediterranean fever (FMF), light chain deposition disease complicating, 942-946
- Families
 of kidney donors, patient attitudes toward offering funeral expenses to, 414
 of renal transplant candidates, effects of education program for, on living donor rates, 739-745
 see also Family history entries beginning with term: Familial
- Family history
 of heart disease, atherosclerotic vascular complications in renal transplant candidates and, 602
 of urolithiasis patients, 209
- Fanconi's syndrome, nonacidotic proximal tubulopathy compared with, 493
- Fe (iron)
 cytochrome P-450 as source of catalytic, in myoglobinuric ARF, 471-472
 gentamicin-induced mobilization of, from renal cortical mitochondria, 467-468
 in hypokalemic metabolic acidosis with hypermagnesuric hypermagnesemia and severe hypocalciuria, 108
 serum, screening for, prior to starting rHuEPO therapy of ESRD patients, 652
 see also Fe in CRF and/or ESRD patients on HD and on rHuEPO therapy
- Fe (iron) in CRF and/or ESRD patients on HD and on rHuEPO therapy, 319-333
 and Fe metabolism, *see* Metabolism, Fe
 Fe status evaluation in, 322
 ferritin and, *see* Serum ferritin in CRF and/or ESRD

- management of, *see* Therapy and management of Fe in CRF and/or ESRD patients on HD and on rHuEPO therapy
- soluble transferrin receptor in, 325
- transferrin saturation and, 323-324
- zinc protoporphyrin and, 325
- Felodipine for hypertension with impaired cognitive function, MRI evidence of white matter, and multi-infarct disease, 4:A2, 4:A9
- Femoral vein catheters, recirculation with, 480
- Ferritin, *see* Serum ferritin in CRF and/or ESRD
- Fibrillary glomerulonephritis (FGN)
- associated with HCV infection, 132-135
- with hematuria and renal insufficiency, 806-810
- Fibroblasts, skin, collagen mRNA in, in IDDM nephropathy patients, 4:A4, 4:A20
- Fibrosis, glomerular diseases due to ECM accumulation, excessive cell proliferation and, ETs in, 14-15
- Financial incentives for kidney donation, patient attitudes toward, 410-418
- Fistulas
- AV, *see* Arteriovenous fistula
- PTFE graft, effects of aspirin or ticlopidine on platelet deposition on, 560-564
- FK-506 (tacrolimus), 305-307
- and polyomavirus-induced interstitial nephritis in renal transplant recipients, 754-758
- Fluid and electrolytes
- ET effects on tubular transport of, 8-10
- see also specific electrolytes*
- fMf (familial Mediterranean fever), light chain deposition disease complicating, 942-946
- Focal segmental glomerulosclerosis (FSGS)
- and IgAN, 528
- with NS, *see* Focal segmental glomerulosclerosis with NS
- platelet function in, 4:A3, 4:A5
- role of oncotic pressure in, 147-152
- SDS-PAGE characterization of proteinuria in, 27-35
- unilateral, RAS and, 936-941
- Focal segmental glomerulosclerosis (FSGS) with NS
- in cholesterol atheroembolism, 334-344
- relapsing NS, minimal change NS, C1q nephropathy and, 966-970
- Folate, screening for, prior to starting rHuEPO therapy of ESRD patients, 652
- Food preferences of ESRD patients on CAPD and after renal transplantation, 694
- Fosinopril, chronic therapy with, in older hypertensive patients with chronic renal insufficiency, racial differences in renal response to, 897-906
- Fractional area of interstitium (IFA) in arteriolar sclerosis, 912-918
- Fractional distal (and proximal) solute reabsorption in hypokalemic metabolic alkalosis with hypomagnesuric hypermagnesemia and severe hypocalciuria, 106-114
- Free radicals
- anti-O₂ tea polyphenol, for CRF, 4:A3, 4:A7
- see also* Oxidants in toxic ARF
- FSGS, *see* Focal segmental glomerulosclerosis
- Funeral expenses, patient attitudes toward offering, to families of kidney donors, 414
- Fungal disease, systemic entomophthoromycosis as, severe hypertension secondary to, 620-623
- Fusion proteins, costimulatory signals and, in immunosuppression, 311
- Gamma (γ)-glutamyl transpeptidase (GGT) in HCV-positive ESRD patients, 610, 611
- Gastric juice NH₃ (ammonia) following *H. pylori* eradication in ESRD patients on dialysis, 87-88
- Gastrin, serum, following *H. pylori* eradication in ESRD patients on dialysis, 87-88
- Gender, *see* Sex
- General biology of ETs, 2-3
- General health care for ESRD women on dialysis, 688
- General population
- Ca metabolism in, 641-642
- quality of life of, compared with quality of life of ESRD patients 3 months after start of chronic HD and/or PD, 587-588
- Genetics, *see* Inheritance
- Genotype
- ACE, IgAN prognosis and, 819
- lack of relationship between enzymic phenotype, severity of PH1 and, 36-44
- Gentamicin nephrotoxicity, oxidant role in, 466-468
- Geographic distribution of renal physicians, 783-784
- GF, *see* Growth factor
- GFR, *see* Glomerular filtration rate
- GGs (global glomerulosclerosis)/chronic vascular disease in FSGS with NS, 339
- GGT (gamma-glutamyl transpeptidase) in HCV-positive ESRD patients, 610, 611
- Global glomerulosclerosis (GGs)/chronic vascular disease in FSGS with NS, 339
- Glomerular diseases, *see* Glomerulopathy
- Glomerular epithelial cells, ETs in, 7
- Glomerular filtration rate (GFR)
- in arteriolar sclerosis, 914
- critical renal perfusion pressure and, in IRD, 169
- in elderly hypertensive patients with chronic renal insufficiency, effects of chronic ACE inhibition on, 897-906
- in long-term renal transplant recipients, 747, 749
- see also* Glomerular filtration rate, ET-1 and; Glomerular filtration rate in CRF and/or ESRD; Glomerular filtration rate in HTN; Hyperfiltration; Mesangial cell(s), GFR regulation by
- Glomerular filtration rate (GFR), ET-1 and, 4
- in ischemic renal failure, 12
- in toxin-related renal injury, 14
- Glomerular filtration rate (GFR) in CRF and/or ESRD, 505
- MDRD study and, 888-896
- residual, 3 months after start of chronic HD and/or PD, 586, 589
- in secondary HPT with CRF, 499
- Glomerular filtration rate (GFR) in HTN
- effects of antihypertensive therapy on, race and, 720-728
- endogenous EPO and, 377
- Glomerular hypertension (HTN) in FSGS, 147-152
- Glomerulointerstitial interaction of adhesion molecules in IgAN and MPGN, 843-850
- Glomerulonephritis (GN)

- crescentic, *see* Crescentic glomerulonephritis
- CRF and, *see* Glomerulonephritis, CRF and/or ESRD and
- fibrillary, hematuria in, 806-810
- with HCV infection, *see* Glomerulonephritis with HCV infection
- ketoconazole and low-dose prednisone effects on progression of, 503-513
- membranoproliferative, *see* Membranoproliferative glomerulonephritis
- membranous, *see* Membranous glomerulonephritis
- necrotizing, *see* Necrotizing glomerulonephritis
- postinfectious, during pregnancy, ARF due to, 273-279
- primary, steroid effects on lymphocytes in, 4:A3, 4:A17
- proteinuria in, characterized with SDS-PAGE, 27-35
- in transplant recipients, 420
- see also specific conditions*
- Glomerulonephritis (GN), CRF and/or ESRD and, 412, 414
- albumin concentrations and, 660
- early death prediction and, 216
- with HPT, 863
- in in-center HD patients, 854, 856
- in inner-city renal transplant residents, 883
- quality of life and, 586, 588
- Glomerulonephritis (GN) with HCV infection, 610, 611
- fibrillary, 132-135
- immune complex, with HIV and HCV infections, 514-525
- Glomerulopathy
- CRF and, 505, 507, 891
- with excessive cell proliferation, ECM accumulation, and fibrosis, ETs in, 14-15
- HIV-associated, *see* Glomerulopathy, HIV-associated
- see also specific glomerular diseases*
- Glomerulopathy, HIV-associated
- collapsing glomerulopathy with IC deposits and HIV and HCV infections, 519-520
- prednisone for, 4:A3, 4:A12
- Glomerulosclerosis (GS)
- global, with chronic vascular disease in FSGS with NS, 339
- see also* Focal segmental glomerulosclerosis
- Glomerulus
- ETs in, 6-7
- see also entries beginning with term: Glomerular and element: Glomerulo-*
- Glucose
- in ESRD before and after CAPD and after renal transplantation, 695, 696
- following parathyroidectomy for secondary HPT in HD patients, 760
- hyperglycemia with hypernatremia in non-diabetic patients, 4:A4, 4:A14
- in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446
- mesangial cell, in diabetic nephropathy, 153-163
- postural hemodilution in nephrotic edema and, 628
- Glucose polymer-containing peritoneal dialysis fluids (PDFs), effects of, on phagocytic activity, 246-253
- Glutamate pyruvate transaminase, serum, *see* Alanine transaminase
- Glutamic acid, in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446
- Glutamic-oxaloacetic transaminase, *see* Aspartate transaminase
- Glutamine in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446
- γ (gamma)-Glutamyl transpeptidase in HCV-positive ESRD patients, 610, 611
- Glutathione (GSH), role of, in glycerol-induced ARF, 472-473
- Glyburide, oral, in NIDDM patients with and without ESRD, pharmacokinetics of, 907-911
- Glycerol, toxic ARF due to, 468-474
- Glycine in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446
- Glycosuria in nonacidotic proximal tubulopathy with hypercalciuria, 493
- Glycosylated Hb (hemoglobin) in NIDDM, 908
- GN, *see* Glomerulonephritis
- Gonadal hormones, sex and effects of, on progression of ADPKD, 265-272
- Grading, *see* Histologic grading of IgAN
- Granulocytes, serum factors inhibiting adherence of monocytes and, to saphenous vein endothelial cells during HD, 78-85
- Gross hematuria in IgAN, 833
- Growth, tubular, in chronic metabolic acidosis, 296-297
- Growth factor (GF)
- elevated hepatocyte, in children with biliary atresia, 188-192
- platelet-derived growth factor A and B and Lp effects on mesangial cell proliferation, 922-924
- see also* Transforming growth factor- β
- GS, *see* Glomerulosclerosis
- GSH (glutathione), role of, in glycerol-induced ARF, 472-473
- Guidewire catheter replacement, silicon dual-lumen catheters for long-term HD vascular access with, 553-559
- Gynecologic issues in dialyzed patients, 685-690
- H⁺ (hydrogen), tubular secretion of, in chronic metabolic acidosis, 294
- H pylori* (*Helicobacter pylori*), eradication of, with amoxicillin and proton-pump inhibitor in dialysis patients with ESRD, 86-90
- Hand, painful, pulse oxymetry of O₂ saturation in upper extremity with AV fistula before and after HD, 230-232
- Hb (hemoglobin)
- glycosylated, in NIDDM, 908
- in predialysis patients, rHuEPO and, 543
- see also* Hb in CRF and/or ESRD patients on CAPD and/or HD
- Hb (hemoglobin) in CRF and/or ESRD patients on CAPD and/or HD
- and Ab response to HBV vaccine, 240
- before and after CAPD and after renal transplantation, 695
- in chronic HD patients, nandrolone decanoate effects on, 571
- effects of multidisciplinary predialysis interventions on, 536
- rHuEPO resistance and, 567
- 3 months after start of chronic HD and/or PD, 586, 589
- HBV (hepatitis B virus) vaccine, factors influencing Ab response to, in HD patients, 239-245

- HCMA, *see* Hyperchloremic metabolic acidosis
- HCO₃ (bicarbonate)
 in ESRD, *see* HCO₃ in ESRD
 in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446
 postural hemodilution in nephrotic edema and, 628
 in tubular acidosis, 137-138, 141, 144
- HCO₃ (bicarbonate) in ESRD
 before and after CAPD and after renal transplantation, 695, 696
 with HPT, 863, 864
- Hct, *see* Hematocrit
- HCV, *see* Hepatitis C virus infection
- HD, *see* Hemodialysis
- HDL-C, *see* High-density lipoprotein-cholesterol
- Health insurance coverage, and unemployment among inner-city renal transplant recipients, 881-887
- Heart disease, family history of, and atherosclerotic vascular complications in renal transplant candidates, 602
- Heart rate (HR), and rHuEPO in predialysis CRF patients, 543
- Helicobacter pylori* (*H. pylori*), eradication of, with amoxicillin and proton-pump inhibitor in dialysis patients with ESRD, 86-90
- Hematocrit (Hct)
 in ARF due to postinfectious nephritis in pregnancy, 274
 see also Hematocrit in CRF and/or ESRD
- Hematocrit (Hct) in CRF and/or ESRD
 with HIVAN, 551
 nifedipine effects on, 234
 parenteral Fe effects on, 328
 and rHuEPO in predialysis patients, 543
- Hematuria
 in ICGN with HIV and HCV infections, 516
 in IgAN, 527, 528, 833
 nephrotic syndrome with renal insufficiency and, renal biopsy of, 806-810
- Heme-oxygenase in glycerol-induced ARF, 473-474
- Hemodialysis (HD)
 chronic, *see* Chronic hemodialysis
 compartmental volume loss during, 4:A1, 4:A11
 for CRF and/or ESRD, *see* Hemodialysis for CRF and/or ESRD
 home, for patients trained in self-care CAPD, 4:A1, 4:A10
 for HPT, *see* Hemodialysis for HPT
 intermittent, for ARF, 796
 mortality of patients on, 4:A1, 4:A8
 Na ramping in, beneficial and adverse effects of, 669-677
 pulse oxymetry of O₂ saturation in upper extremity with AV fistula before and after, 230-232
 RenaGel effects on serum P and PTH in patients on, 4:A1, 4:A6
 serum factors inhibiting adherence of monocytes and granulocytes to HSVECs during, 78-85
 vascular access for, *see* Vascular access for HD
- Hemodialysis (HD) for CRF and/or ESRD
 ABPM in patients on, 593-600
 albumin in, *see* Albumin in CRF and/or ESRD patients on CAPD and/or HD
 B cells in response to HBV vaccine in patients on, 241
 Ca and phosphate metabolism with, *see* Ca and phosphate metabolism management in CRF and/or ESRD
 chronic, *see* Chronic hemodialysis
 dialysate Na effects on hypertension in, 383-391
 dyslipidemia and, 54-65
 early mortality in patients starting HD, 214-222
 factors influencing Ab response to HBV vaccine in patients on, 239-245
 HPT and, *see* Hemodialysis for HPT; Hemodialysis for secondary HPT
 in-center, improvement of adequacy of (1993-1995), 851-861
 risk of hospitalization and, 4:A1, 4:A7-A8
 sertraline hydrochloride effects on hypotension due to, 4:A1, 4:A8
 and severe hypocalcemia and hypophosphatemia following parathyroidectomy, 759-762
 SLE development 14 years after commencing, 631-632
 see also Dialysis for CRF and/or ESRD; Patient survival on HD; Recombinant human erythropoietin for CRF and/or ESRD patients on CAPD and/or HD
- Hemodialysis (HD) for HPT, 862-865
 hyperphosphatemia and, 66-71
 see also Hemodialysis for secondary HPT; Hypophosphatemia, HPT and, HD for
- Hemodialysis (HD) for secondary HPT
 for advanced secondary HPT, calcitriol effects on, 4:A1, 4:A6-A7
 and biochemistry following parathyroidectomy, 759-762
- Hemodilution, postural, in nephrotic edema, as cause of hemorrhage following renal biopsy, 627-630
- Hemodynamics, *see* Blood pressure; Heart rate; Renal hemodynamics and entries beginning with terms: Blood flow
- Hemoglobin, *see* Hb
- Hemoglobinopathy J-Meinung, heterozygous, resistance to rHuEPO in ESRD with, 769-772
- Hemolytic uremic syndrome (HUS)
 ARF with, pleural effusion complicating PD of, 4:A1, 4:A6
 endotheliopathy as continuum of, due to MMC therapy, 280-284
- Hemorrhage following renal biopsy, postural hemodilution in nephrotic edema as cause of, 627-630
- Henoch-Schönlein purpura (HSP)
 with IgA and IgA abnormalities in WAS carrier, 285-287
 recurrence of, with IgA ANCA, 125-131
- Heparin-induced thrombocytopenia and thrombosis, pseudo-pulmonary embolism and, 449-452
- Hepatitis B virus (HBV) vaccine, factors influencing Ab response to, in HD patients, 239-245
- Hepatitis C virus (HCV) infection
 ESRD patients with, renal transplantation effects on survival of, 608-614
 as factor influencing Ab response to HBV vaccine in HD patients, 239-245
 see also Glomerulonephritis with HCV infection
- Hepatocyte growth factor (HGF), elevated, in children with biliary atresia, 188-192
- Heterozygous hemoglobinopathy J-Meinung, resistance to rHuEPO in ESRD with, 769-772
- Heymann nephritis, passive, renoprotective properties of lisinopril in, 254-264

- HGF (hepatocyte growth factor), elevated, in children with biliary atresia, 188-192
- HHd (home hemodialysis) in trained self-care CAPD patients, 4:A1, 4:A10
- High-bone turnover, HPT and, in normocalcemic long-term renal transplant recipients, 746-753
- High-density lipoprotein-cholesterol (HDL-C) in CRF, 57, 60 in diabetic renal transplant candidates, 602
- High-school students, BP and urine analysis of, 4:A2, 4:A15
- Histidine in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446
- Histologic grading of IgAN of biopsy specimens, 821-822 new systems of, 953-958
- Histology and histopathology of arteriolar sclerosis, 914 of FSGS with NS in CAE, 338-340 of IgAN, *see* Histology and histopathology, IgAN of IRD, 169-170 of passive Heymann nephritis, 258-259 *see also* Renal biopsy
- Histology and histopathology, IgAN, 527, 530 histologic subclassification, 829-842 *see also* Histologic grading of IgAN
- History of renal work notion and nonpharmacological therapies, 777-780 *see also* Family history; Natural history
- HIV infection, *see* Human immunodeficiency virus infection
- HIVAN, *see* Human immunodeficiency virus-associated nephropathy
- HLAs (human leukocyte antigens) and Ab response to HBV vaccine in HD patients, 241 in familial idiopathic membranous nephropathy, 115-118 peptides derived from, as immunosuppressants, 311-312
- H₂O₂ (hydrogen peroxide), gentamicin-enhanced generation of, toxic ARF and, 466-467
- Home hemodialysis (HHd) in trained self-care CAPD patients, 4:A1, 4:A10
- Homeostatic response to chronic metabolic acidosis, 294-300
- Hospitalization risk of, for HD patients, 4:A1, 4:A7-A8 *see also* Hospitalized patients
- Hospitalized patients early detection and management of hypertensive and diabetic renal disease in, 368-375 for ESRD, suboptimal dialysis delivery in, 4:A2, 4:A14-A15
- HPT, *see* Hyperparathyroidism
- HR (heart rate), and rHuEPO in predialysis CRF patients, 543
- HSP, *see* Henoch-Schönlein purpura
- HSVECs (human saphenous vein endothelial cells), serum factors inhibiting adherence of monocytes and granulocytes to, during HD, 78-85
- HTN, *see* Hypertension
- Human immunodeficiency virus-associated nephropathy (HIVAN) HD for ESRD with, 549-552 ICGN and, 514-525 response of, to long-term corticosteroid therapy, 624-626
- Human immunodeficiency virus (HIV) infection ESRD and, 653 HD for ESRD with, 549-552 ICGN with HCV and, 514-525 *see also* Glomerulopathy, HIV-associated
- Human leukocyte antigens, *see* HLAs
- Human saphenous vein endothelial cells (HSVECs), serum factors inhibiting adherence of monocytes and granulocytes to, during HD, 78-85
- Hungry bone syndrome (severe hypocalcemia with hypophosphatemia) following parathyroidectomy for secondary HPT in ESRD patients on HD, 759-762
- HUS, *see* Hemolytic uremic syndrome
- Hyalinosis, arteriolar, in proteinuric GN, 30, 31
- Hydrogen (H⁺), tubular secretion of, in chronic metabolic acidosis, 294
- Hydrogen peroxide (H₂O₂), gentamicin-enhanced generation of, toxic ARF and, 466-467
- 25-Hydroxycholecalciferol [25(OH)D], serum, in long-term renal transplant recipients, 747, 749
- Hypercalcemia, HPT with hypophosphatemia and, HD with conventional Ca-containing solution enriched with P for, 288-290
- Hypercalciuria in nonacidotic proximal tubulopathy, 490-495
- Hyperchloremic metabolic acidosis (HCMA), 141-144 case studies of, 143-144 clinical approach to, 141-143
- Hypercholesterolemia, myocardial infarction, renal artery stenosis and, 734
- Hyperfiltration in FSGS, 147-152
- Hyperglycemia with hyponatremia in non-diabetic patients, 4:A4, 4:A14
- Hyperinflammatory response, PS deficiency and, 931-935
- Hyperkalemia following parathyroidectomy for secondary HPT in HD patients, 762 trimethoprim-sulfamethoxazole and, 959-965
- Hypermagnesemia, hypomagnesuric, hypokalemic metabolic alkalosis with severe hypocalciuria and, 106-114
- Hyponatremia, hyperglycemia with, in non-diabetic patients, 4:A4, 4:A14
- Hyperoxaluria, *see* Primary hyperoxaluria; Primary hyperoxaluria type I
- Hyperparathyroid bone disease, calcitriol therapy of, 646-647
- Hyperparathyroidism (HPT) calciphylaxis and, 773-776 HD for, *see* Hemodialysis for HPT high-bone turnover and, in normocalcemic long-term renal transplant recipients, 746-753 with hypophosphatemia, *see* Hypophosphatemia, HPT and, HD for
- Hyperphosphatemia and calciphylaxis in Crohn's disease without ESRD, 773-776 RenaGel as noncalcemic phosphate binder for, in CRF, 66-71 severe, following phosphate administration for bowel preparation in renal failure patients, 103-105
- Hyperphosphaturia, isolated, severe hypophosphatemia and, with multiple myeloma, 445-448

- Hypertension (HTN), 368-391
 correlation between endogenous EPO and, 376-382
 dialysate Na effects on, 383-391
 early detection and management of renal disease with, in hospitalized patients, 368-375
 and ESRD, *see* Hypertension, CRF and/or ESRD and ET-1 in, 15-17
 GFR in, *see* Glomerular filtration rate in HTN
 glomerular, in FSGS, 147-152
 in ICGN with HIV and HCV infections, 516
 IgAN and, 833
 myocardial infarction, renal artery stenosis and, 734
 portal, bleeding esophageal varices and, due to ADPKD, 4:A3, 4:A18
 race and, *see* Hypertension, race and
 in renal transplant recipients, 420, 883
 as risk factor for presence of atherosclerotic RAS in IRD, 173
 severe, secondary to systemic entomophthoromycosis, 620-623
 therapy of, *see* Antihypertensive therapy
see also specific conditions
- Hypertension (HTN), CRF and/or ESRD and, 412, 414, 679
 albumin concentrations and, 660
 in chronic HD patients, 581
 early death prediction and, 216
 with HCV infection, 610, 611
 with HPT, 863
 in in-center HD patients, 854, 856
 rHuEPO therapy and, 653
- Hypertension (HTN), race and
 and antihypertensive drug effects on GFR, 720-728
 and familial clustering of ESRD with SLE, 731
 racial differences in renal response to chronic fosinopril and/or lisinopril therapy in older hypertensive patients with chronic renal insufficiency, 897-906
 relationship between renal allograft survival and, 419-427
 SLC associated with insulin resistance, albuminuria and, 45-53
- Hypertensive nephrosclerosis, race and, 720-728
- Hypertrophic effects of AII and glucose in diabetic nephropathy, 153-163
- Hypertrophy, left ventricular, and rHuEPO for predialysis CRF patients, 541-548
- Hypoalbuminemia
 in children with biliary atresia, 189
 in CRF and/or ESRD patients on HD, 658-668
- Hypocalcemia
 hyperphosphatemia and, following phosphate administration for bowel preparation in renal failure patients, 103-105
 severe, following parathyroidectomy for secondary HPT in HD patients, 759-762
- Hypocalciuria, severe, hypokalemic metabolic alkalosis with hypomagnesuric hypermagnesemia and, 106-114
- Hypocomplementemia in ICGN patients with HIV and HCV infections, 516
- Hypogonadism, rHuEPO effects on, 4:A2, 4:A11-A12
- Hypokalemia
 in children with biliary atresia, 189
 in nonacidotic proximal tubulopathy with hypercalciuria, 493
- Hypokalemic metabolic alkalosis with hypomagnesuric hypermagnesemia and severe hypocalciuria, 106-114
- Hypomagnesuric hypermagnesemia, hypokalemic metabolic alkalosis with severe hypocalciuria and, 106-114
- Hypophosphatemia
 in nonacidotic proximal tubulopathy, 490-495
see also Ca, hypophosphatemia and; Hypophosphatemia, HPT and, HD for; Severe hypophosphatemia
- Hypophosphatemia, HPT and, HD for
 following parathyroidectomy for secondary HPT in HD patients, 759-762
 with hypercalcemia, HD with conventional Ca-containing solution enriched with P for, 288-290
- Hypotension, HD, sertraline hydrochloride effect on, 4:A1, 4:A8
- Hypouricemia in children with biliary atresia, 189
- IC(s) (immune complexes), collapsing glomerulopathy with deposits of, HIV and HCV infections and, 519-520
- ICAM1 (immune complex adhesion molecule 1)/LFA1 and ICAM3 (immune complex adhesion molecule 3)/LFA1 interactions in IgAN and MPGN, 843-850
- ICGN (immune complex glomerulonephritis) with HIV and HCV infection, 514-525
- IDDM (insulin-dependent diabetes mellitus), *see* Diabetes mellitus
- Identical twins, idiopathic membranous nephropathy in, 115-118
- Idiopathic membranous nephropathy (IMN)
 in the elderly, therapy of, 200-206
 in identical twins, 115-118
- IDLs (intermediate-density lipoproteins), effects of, on mesangial cell proliferation, 919-930
- IFA (fractional area of interstitium) in arteriolar sclerosis, 912-918
- IgA (immunoglobulin A)
 in ascitic patients, 395
 IgAN with abnormalities of, and HSP in WAS carrier, 285-287
- IgA (immunoglobulin A) antineutrophil cytoplasmic antibodies (ANCA), IgAN recurrence with, 125-131
- IgA nephropathy (IgAN; Berger's disease)
 glomerulointerstitial interaction of adhesion molecules in, 843-850
 hemorrhological alterations in, 4:A3, 4:A14
 histologic grading of, *see* Histologic grading of IgAN
 HSP with IgA abnormalities and, in WAS carrier, 285-287
 natural history and risk factors for, 526-532
 progression of, to ESRD, *see* Progression of (and to) CRF and/or ESRD, IgAN
 recurrence of, with IgA ANCA following renal transplantation, 125-131
see also Renal biopsy in IgAN
- IgAN, *see* IgA nephropathy
- IgG (immunoglobulin G) in ascitic patients, 395
- IgM (immunoglobulin M) in ascitic patients, 395
- IHD (intermittent hemodialysis) for ARF, 796
- IL-, *see entries beginning with term: Interleukin-*
- IMCD (inner medullary collecting duct), fluid and electrolyte transport by, ET effects on, 8-10
- Immune cells, interstitial expression of ICAM1 and ICAM3 and interstitial infiltration of, 844-845

- Immune complex(es) (ICs), collapsing glomerulopathy with deposits of, HIV and HCV infections and, 519-520
- Immune complex adhesion molecule 1 (ICAM1)/LFA1 and immune complex adhesion molecule 3 (ICAM3)/LFA1 interactions in IgAN and MPGN, 843-850
- Immune complex glomerulonephritis (ICGN) with HIV and HCV infection, 514-525
- Immunogenetic markers of IgAN prognosis, 818-819
- Immunoglobulin, *see entries beginning with acronym*
- Ig
- Immunosuppression, *see Clinical studies and trials of new immunosuppressive agent(s) and specific immunosuppressive agents*
- IMN, *see Idiopathic membranous nephropathy*
- In-center hemodialysis (HD) for CRF and/or ESRD, improvement in delivery of (1993-1995), 851-861
- Income level
- and attitudes toward financial incentives for kidney donation, 412, 414
 - of inner-city renal transplant residents, unemployment and, 883-885
- Indications
- for dialysis in ARF, 796
 - for renal biopsy in IgAN, 527
 - for tunnelled permanent venous catheters, 4:A2, 4:A16
- see also specific conditions*
- Infarction
- felodipine for hypertension with impaired cognitive function, MRI evidence of white matter, and multi-infarct disease, 4:A2, 4:A9
 - myocardial, *see Myocardial infarction*
- Infections
- ARF due to GN following, during pregnancy, 273-279
 - opportunistic, in renal transplantation, 754-758
 - PD-related, *see Infections, PD-related*
 - silicon dual-lumen catheter-related, 556-557
- see also specific infections*
- Infections, PD-related
- povidone-iodine ointment in prevention of, 763-768
- see also Exit-site infections, catheter; Peritonitis on CAPD; Tunnel infections*
- Inflammation
- and albumin concentrations in ESRD patients on HD, 658-668
 - hyperinflammatory response and PS deficiency, 931-935
- Inheritance
- vertical PH1, 36-44
- see also Alleles; Families; Genotype; mRNA; Phenotype entries beginning with terms: Autosomal dominant, Heterozygous and specific inherited conditions*
- Injury, *see Myocardial injury; Renal injury*
- Inner-city renal transplant recipients, unemployment among, 881-887
- Inner medullary collecting duct (IMCD), fluid and electrolyte transport by, ET effects on, 8-10
- Insulin
- in ESRD before and after CAPD and after renal transplantation, 695, 696
- see also Insulin resistance*
- Insulin-dependent diabetes mellitus, *see Diabetes mellitus*
- Insulin resistance, 45-65
- role of abdominal adiposity and, in dyslipidemia of CRF, 54-65
- SLC associated with albuminuria and, race and, 45-53
- Integrin, and monocyte and granulocyte adherence to HSVECs during HD, 78-85
- α (alpha)-Interferon for fibrillary GN associated with HCV infection, 132-135
- Interleukin-1 β (IL-1 β), and Lp effects on mesangial cell proliferation, 926-927
- Interleukin-4 (IL-4), effects of, on neutrophil infiltration in nephritis, 4:A3, 4:A16-A17
- Interleukin-6 (IL-6), and Lp effects on mesangial cell proliferation, 921-922
- Interleukin-8 (IL-8), expression of, following renal transplantation, rejection and, 871-880
- Intermediate-density lipoproteins (IDLs), effects of, on mesangial cell proliferation, 919-930
- Intermittent hemodialysis (IHD) for ARF, 796
- Interstitial nephritis
- CRF and, *see Interstitial nephritis, CRF and/or ESRD and effects of ketoconazole and low-dose prednisone on progression of, 503-513*
 - polyomavirus-induced, in renal transplant recipients, 754-758
- Interstitial nephritis, CRF and/or ESRD and chronic, 653
- in chronic HD patients, residual renal function preservation with PS dialyzers and, 581
 - quality of life and, 586, 588
- Interstitial
- fractional area of, in arteriolar sclerosis, 912-918
 - immune cell infiltration into, ICAM1 and ICAM3 expression and, 844-845
- see also entries beginning with terms: Glomerulointerstitial, Interstitial*
- Intestinal Ca (calcium), calcitriol effects on absorption of, 642
- Intestinal flora, and Cr degradation in CRF, 72-77
- Intradialytic parenteral nutrition, effects of, on Ku/V, 4:A2, 4:A12-A13
- Intradialytic symptoms, Na ramping and, 671-672
- Ionic mechanisms, 974-976
- of mesangial cell contraction, 974-975
 - of mesangial cell relaxation, 975-976
- IRD, *see Ischemic renal disease*
- Iron, *see Fe*
- Iron saccharate in CRF patients on HD, rHuEPO resistance and, 567
- Ischemic renal disease (IRD), 167-187
- anatomic correlates of, 168-169
 - causes of, 167-168
 - clinical presentation of, 175-176
 - defined, 167
 - diagnosis of, 176-178
 - natural history of, 173-174
 - pathophysiology of, 169-171
 - prevalence of, 175
 - prevalence of atherosclerotic RAS in, 171-173
 - renal artery stenosis and, 733-738
 - survival with, 182-183
 - therapy of, 179-182
- Ischemic renal failure
- ETs in, 12

- see also* Ischemic renal disease
- Isoflurane, effects of, on proximal tubular cell energetics, 4:A1, 4:A12
- Isolated hyperphosphaturia, severe hypophosphatemia and, with multiple myeloma, 445-448
- Isolated proximal renal tubular acidosis (pRTA), 143
- Isoleucine in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446
- Japanese subjects, natural history and risk factors for IgAN in, 526-532
- K (potassium)
- ACE inhibitor effects on, 4:A2, 4:A20-A21
- effects of depletion of, on cortical and medullary membrane protein and lipids, 4:A4, 4:A8-A9
- following parathyroidectomy for secondary HPT in HD patients, 760
- in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446
- plasma, in ascitic patients, 394
- postural hemodilution in nephrotic edema and, 628
- serum, *see* Serum K
- see also* Hyperkalemia; Hypokalemia; Hypokalemic metabolic alkalosis
- Ketoconazole, effects of low-dose prednisone and, on progression of CRF, 503-513
- Kidneys
- donation of, *see* Donors
- weight of, in ADPKD, 267-268
- see also* entries beginning with term: Renal and element: Neph-
- Kinase, CK-MB and myocardial injury diagnosis in chronic HD patients, 399-403
- Kt/V
- and Ab response to HBV vaccine, 240
- intradialytic parenteral nutrition effects on, 4:A2, 4:A12-A13
- nifedipine effects on, 234
- in peripheral AV versus CVV access, 487-488
- 3 months after start of chronic HD and/or PD, 586, 589
- see also* Dialysis delivery; Urea reduction ratio
- Lactate, levels of, in glucose polymer-containing PDFs, 247
- Lactate dehydrogenase (LDH) in ARF due to postinfectious GN during pregnancy, 274
- LD(s) (living donors), increase in, with formal education program for families of renal transplantation candidates, 739-745
- LDL(s), *see* Low-density lipoprotein(s)
- LDL-C, *see* Low-density lipoprotein-cholesterol
- Lectin, binding of, to IgA in IgAN with HSP in WAS carrier, 286
- Leflunomide, 308
- Left ventricular hypertrophy (LVH), and rHuEPO for predialysis CRF patients, 541-548
- Leucine in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446
- Leukocytes, *see* White blood cell count and specific leukocytes
- LFA1, ICAM1 and ICAM3 interactions with, in IgAN and MPGN, 843-850
- Li, *see* Lithium
- Light chain deposition disease complicating fMF, 942-946
- Line reversal, recirculation and, in peripheral AV versus CVV access, 482-483
- Lipids
- cortical and medullary membrane, effects of K depletion on, 4:A4, 4:A8-A9
- level of, in diabetic renal transplant candidates, 602
- postural hemodilution in nephrotic edema and, 628
- role of insulin resistance and abdominal adiposity in dyslipidemia of CRF, 54-65
- serum, androgen effects on levels of, in chronic HD patients, 569-575
- see also* specific lipids
- Lipoprotein (Lp)
- effects of, on mesangial cell proliferation, 919-930
- nandrolone decanoate effects on concentrations of, in chronic HD patients, 569-575
- see also* Intermediate-density lipoproteins; Lipoprotein(a); Low-density lipoprotein(s)
- Lipoprotein(a) [Ip(a)]
- in CRF, 57
- as CV risk factor in dialyzed ESRD patients, 4:A2, 4:A13
- serum, nandrolone decanoate effects on concentrations of, in chronic HD patients, 569-575
- Lisinopril
- chronic therapy with, in older hypertensive patients with chronic renal insufficiency, racial differences in renal response to, 897-906
- renoprotective properties of, in membranous nephropathy, 254-264
- Lithiasis, *see* Nephrolithiasis; Urolithiasis
- Lithium (Li)
- ESRD following therapy with, 4:A3, 4:A7
- insulin resistance and albuminuria associated with sodium-lithium countertransport, race and, 45-53
- tubular cysts, adenoma, and adenocarcinoma due to, 4:A3, 4:A5
- Livedo reticularis, primary hyperoxaluria with renal failure, retinopathy, and peripheral neuropathy, 947-952
- Liver disease, autosomal dominant polycystic, portal hypertension and bleeding esophageal varices due to, 4:A3, 4:A18
- Living donors (LDs), increase in, with formal education program for families of renal transplantation candidates, 739-745
- LMW (low molecular weight; tubular) proteins in GN with proteinuria, clinical significance and prognostic value of, 27-35
- Long-term corticosteroid therapy of HIVAN, response to, 624-626
- Long-term renal transplant recipients, normocalcemic, high-bone turnover and HPT in, 746-753
- Long-term vascular access for HD, catheters for silicon dual-lumen catheters with guidewire replacement of catheters, 553-559
- tunneled permanent venous catheters for, 4:A2, 4:A16
- Low-density lipoprotein(s) (LDLs)
- in CRF, 60
- effects of, on mesangial cell proliferation, 919-930
- see also* Low-density lipoprotein-cholesterol

- Low-density lipoprotein-cholesterol (LDL-C)
in CRF, 57
in diabetic renal transplant candidates, 602
- Low-dose prednisone, effects of ketoconazole and, on progression of CRF, 503-513
- Low molecular weight (tubular; LMW) proteins in GN with proteinuria, clinical significance and prognostic value of, 27-35
- Low-turnover bone disease, calcitonin effects in dialysis patients with, 4:A2, 4:A19
- Lp, *see* Lipoprotein
- Lupus nephritis
diffuse proliferative, PS deficiency and, 931-935
HCV infection and, 610
membranous, with P-ANCA-associated pauci-immune segmental necrotizing GN, 119-124
meta-analysis of treatment of, 193-199
see also Systemic lupus erythematosus
- LVH (left ventricular hypertrophy), and rHuEPO for predialysis CRF patients, 541-548
- Lymphocytes
corticosteroid effects on, in primary GN, 4:A3, 4:A17
in HD patients, *see* Lymphocytes in HD patients
- Lymphocytes in HD patients
effects of nifedipine discontinuation on cytosolic Ca and B cell proliferation with CRF, 233-238
phenotyping of, effects of rHuEPO on phagocyte activity and, 866-870
in response to HBV vaccine, 241
- Lysine in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446
- Macrophage population, cancer antigen 125 and dialysate, in stable CAPD patients, peritoneal transport parameters and, 699-705
- Magnesium, *see* Mg
- Magnetic resonance imaging (MRI), felodipine for hypertension with impaired cognitive function, multi-infarct disease, and evidence of white matter as seen with, 4:A2, 4:A9
- Malignant disease, *see* Multiple myeloma; Renal transplantation in patients with malignant disease
- MAP (mean arterial pressure), *see* Blood pressure
- Marital status
and quality of life 3 months after start of chronic HD and/or PD, 586
vasectomy as risk factor for urolithiasis and, 209
- MC(s), *see* Mesangial cell(s)
- MCNS, *see* Minimal change nephrotic syndrome
- MDRD (Modification of Diet in Renal Disease) study of quality of life with CRF, 888-896
- Mean arterial pressure, *see* Blood pressure
- Medical management
of IRD, 182
see also Therapy and management and specific drugs and specific conditions
- Medical practice, general, future of, 638-639
- Medullary collecting duct, inner, fluid and electrolyte transport by, ET effects on, 8-10
- Medullary membranes, effects of K depletion on lipids and protein of, 4:A4, 4:A8-A9
- Membranoproliferative glomerulonephritis (MPGN)
glomerulointerstitial interaction of adhesion molecules in, 843-850
with HIV and HCV infections, 517-518
SDS-PAGE characterization of proteinuria in, 27-35
- Membranous glomerulonephritis (GN)
IgAN and, 528
SDS-PAGE characterization of proteinuria in, 27-35
SLE and uterine vasculitis with, 277-279
- Membranous lupus nephritis with P-ANCA-associated pauci-immune segmental necrotizing GN, 119-124
- Membranous nephropathy (MN)
with HIV and CV infections, 519
idiopathic, *see* Idiopathic membranous nephropathy
renoprotective properties of lisinopril in, 254-264
- Memphis scoring system for renal biopsy findings in IgAN, 825-826
- Mesangial cell(s) (MCs), 147-163
ETs in, 6-7
in FSGS, 147-152
glucose in, in diabetic nephropathy, 153-163
LP effects on proliferation of, 919-930
see also Mesangial cell(s), GFR regulation by
- Mesangial cell(s) (MCs), GFR regulation by, 971-981
capillary-mesangial biomechanical unit in, 972
effects of disease on mesangial cell tone in, 976-977
GFR regulation by vasoactive agents and, 972-973
mesangial cell contraction in, *see* Mesangial cell contraction in GFR regulation
mesangial cell relaxation in, 975-976
- Mesangial cell (MC) contraction in GFR regulation, 973-976
mechanisms of, 973-975
renal disease and impaired, 976
- Mesangial proliferative glomerulonephritis (GN) with HIV and HCV infections, 518-519
- Mesothelial cells
cancer antigen 125 dialysate population of, in stable CAPD patients, peritoneal transport parameters and, 699-705
effects of PDFs on, 404-409
- Messenger ribonucleic acid, *see* mRNA
- Metabolic acidosis
influence of, on nutrition, 5:xlvi-xlviii
see also Chronic metabolic acidosis; Hyperchloremic metabolic acidosis
- Metabolic alkalosis, hypokalemic, with hypomagnesuric hypomagnesemia and severe hypocalcemia, 106-114
- Metabolism
bone, with reduced renal function, 4:A3, 4:A9
see also Ca and phosphate metabolism management in CRF and/or ESRD; Metabolism, Fe and entries beginning with term: Metabolic
- Metabolism, Fe, 320-322
in ESRD, 321-322
normal, 320-321
- Metalloproteinase-1 (MMP-1) mRNA (messenger ribonucleic acid) in skin fibroblasts of diabetic nephropathy patients, 4:A4, 4:A20
- Methionine in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446
- MFs (myofibroblasts), arteriolar sclerosis and, in diabetic nephropathy, 912-918

- Mg (magnesium)
 in glucose polymer-containing PDFs, 247
 in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446
 in hypokalemic metabolic alkalosis with hypomagnesuric hypermagnesemia and severe hypocalciuria, 108
- MI, *see* Myocardial infarction
- Minimal change nephrotic syndrome (MCNS)
 FSGS, C1q nephropathy and, and relapsing NS, 966-970
 platelet function in, 4:A3, 4:A5
- Mitochondria, *see* Renal cortical mitochondria
- Mitomycin C (MMC), endotheliopathy as continuum of HUS due to, 280-284
- Mizoribine, 308-309
- MMC (mitomycin C), endotheliopathy as continuum of HUS due to, 280-284
- MMF (mycophenolate mofetil), 309-310
- MMP-1 (metalloproteinase-1) mRNA (messenger ribonucleic acid) in skin fibroblasts of diabetic nephropathy patients, 4:A4, 4:A20
- MN, *see* Membranous nephropathy
- Modification of Diet in Renal Disease (MDRD) study of quality of life with CRF, 888-896
- Monocytes
 effects of glucose polymer-containing PDFs on activity of, 246-253
 serum factors inhibiting adherence of granulocytes and, to HSVECs during HD, 78-85
- Mortality of HD patients, 4:A1, 4:A8
 early, of ESRD patients starting HD or PD, 214-222
 with silicon dual-lumen HD catheters, 555
see also specific conditions
- MPGN, *see* Membranoproliferative glomerulonephritis
- MPO (myeloperoxidase), and recurrent IgAN with IgA AN-CAs, 125-131
- MRI (magnetic resonance imaging), felodipine for hypertension with impaired cognitive function, multi-infarct disease, and evidence of white matter as seen with, 4:A2, 4:A9
- mRNA (messenger ribonucleic acid)
 collagen, MMP-1, and tissue inhibitor of metalloproteinase-1, in skin fibroblasts of IDDM nephropathy patients, 4:A4, 4:A20
 ECM, effects of lisinopril on expression of, in PHN, 259
- Mucormycosis, pulmonary, in diabetic renal transplant recipients, 461-464
- Multidisciplinary predialysis interventions, 533-540
- Multi-infarct disease, felodipine for hypertension with impaired cognitive function, MRI evidence of white matter and, 4:A2, 4:A9
- Multiple myeloma, isolated hyperphosphaturia with severe hypophosphatemia in, 445-448
- Mycophenolate mofetil (MMF; RS-61443), 309-310
- Myeloma, multiple, isolated hyperphosphaturia with severe hypophosphatemia in, 445-448
- Myeloperoxidase (MPO), and recurrent IgAN with IgA AN-CAs, 125-131
- Myocardial infarction (MI)
 in diabetic renal transplant candidates, 601-607
 prevalence and predictors of renal artery stenosis in, 733-738
- Myocardial injury in chronic HD patients, CK-MB and, 399-403
- Myofibroblasts (MFs), arteriolar sclerosis and, in diabetic nephropathy, 912-918
- Myoglobinuric acute renal failure (ARF), cytochrome P-450 as source of catalytic Fe in, 471-472
- N (nitrogen), *see* Azotemia; Urea nitrogen
- Na (sodium)
 dialysate, effects of, on hypertension, 383-391
 in glucose polymer-containing PDFs, 247
 in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446
 in hypokalemic metabolic alkalosis with hypomagnesuric hypermagnesemia and severe hypocalciuria, 108
 Na ramping in HD, 669-677
 plasma, in ascitic patients, 408
 postural hemodilution in nephrotic edema and, 628
 serum, *see* Serum Na
 urinary excretion of, *see* Urinary excretion, Na
see also Hypernatremia; Natriuretic peptide; Sodium-dodecyl sulphate-polyacrylamide gel electrophoresis; Sodium-lithium countertransport
- NaCl (sodium chloride), dietary, influence of, on antiproteinuric effects of Ca channel blockers, 800-805
- Nandrolone decanoate, serum Lp(a) concentrations reduced by, in chronic HD patients, 569-575
- Natriuretic peptide, atrial, postural hemodilution in nephrotic edema and, 628
- Natural history
 of IgAN, 526-532
 of IRD, 173-174
- Necrotizing glomerulonephritis (GN)
 crescentic, ANCA-associated vasculitis and, 96-102
 pauci-immune segmental, membranous lupus nephritis associated with, 119-124
- Nephritis
 IL-4 effects on neutrophil infiltration in, 4:A3, 4:A16-A17
 passive Heymann, renoprotective properties of lisinopril in, 254-264
see also Glomerulonephritis; Interstitial nephritis; Lupus nephritis; Perinephritis; Pyelonephritis
- Nephrocalcinosis
 nonacidotic proximal tubulopathy and, 493
 PH and, *see* Nephrocalcinosis, PH and
- Nephrocalcinosis, PH and
 PH1, 36-44
 with renal failure, 947-952
- Nephrolithiasis, and nonacidotic proximal tubulopathy, 490-495
- Nephrology, future aspects of, 633-639
 future utilization of nephrology services and supply of renal physicians, 789-790; *see also* Renal physicians, supply of
 nephrology faculty, 636-637
 practice, 638-639
 research, 637
 training of nephrologists, 633-636
- Nephromegaly, elevated HGF in children with biliary atresia and, 188-192
- Nephrosclerosis

- body weight, sex and, 4:A4, 4:A16
 hypertensive, race and, 720-728
- Nephrotic edema, postural hemodilution in, as cause of hemorrhage following renal biopsy, 627-630
- Nephrotic syndrome (NS)
 FSGS and, *see* Nephrotic syndrome, FSGS and
 with hematuria and renal insufficiency, renal biopsy of, 806-810
 IgAN with, 528, 530
 minimal change, *see* Minimal change nephrotic syndrome
- Nephrotic syndrome (NS), FSGS and, 147-152
 in cholesterol atheroembolism, 334-344
- Nephrotoxicity of CsA
 ARF due to, 474-475
 role of ETs in, 12-13
- Nephrotoxin
 in ARF, 795-796
see also Nephrotoxicity of CsA; Toxic acute renal failure
- Neurohumoral substances, and rHuEPO in predialysis CRF patients, 545
- Neuropathy, peripheral, primary hyperoxaluria with renal failure, livedo reticularis, and retinopathy, 947-952
- Neutrophil(s)
 effects of glucose polymer-containing PDFs on activity of, 246-253
 in nephritis, IL-4 effects on infiltration of, 4:A3, 4:A16-A17
- New immunosuppressive agent(s), *see* Clinical studies and trials of new immunosuppressive agent(s)
- NH₃ (ammonia)
 gastric juice, following *H pylori* eradication in ESRD patients on dialysis, 87-88
 synthesis of, in chronic metabolic acidosis, 296
- NH₄ (ammonium)
 synthesis of, in chronic metabolic acidosis, 296
 urinary excretion of, in tubular acidosis, 139-140
- NIDDM (non-insulin-dependent diabetes mellitus), *see* Diabetes mellitus
- Nifedipine, effects of discontinuation of, on cytosolic Ca, and B cell proliferation in CRF patients on HD, 233-238
- Nitrate, excretion of, in CRF, ketoconazole plus low-dose prednisone effects on, 503-513
- Nitric oxide (NO), amino acids and pathway of, in acute peritonitis on CAPD, 712-719
- Nitrite in acute peritonitis on CAPD, 715-716
- Nitrogen, *see* Azotemia; Urea nitrogen
- NO (nitric oxide), amino acids and pathway of, in acute peritonitis on CAPD, 712-719
- Nonacidotic proximal tubulopathy, autosomal dominant, 490-495
- Noncalcemic phosphate binder, *see* RenaGel
- Nondiabetic end-stage renal disease (ESRD) with HPT, 863-864
- Nondiabetic patients, hyperglycemia with hypernatremia in, 4:A4, 4:A14
- Non-insulin-dependent diabetes mellitus, *see* Diabetes mellitus
- Nonpharmacological therapies, renal work notion and introduction of, 777-780
- Nontransport function of renal tubules, effect of tubule-derived ETs on, 11
- Normal Fe (iron) metabolism, 320-321
- Normal population, *see* General population
- Normalized protein catabolic rate (nPCR) 3 months after start of chronic HD and/or PD for CRF and/or ESRD, 586, 589
- Normocalcemic long-term renal transplant recipients, high-bone turnover and HPT in, 746-753
- nPCR (normalized protein catabolic rate) 3 months after start of chronic HD and/or PD for CRF and/or ESRD, 586, 589
- NS, *see* Nephrotic syndrome
- Nutrition, *see* Chronic renal failure, nutrition in; Therapy and management of Fe in CRF and/or ESRD patients on HD and on rHuEPO therapy *entries beginning with terms:* Dietary, Parenteral
- O₂, *see entries beginning with term:* Oxygen
- O₂⁻ (superoxide), effects of glucose polymer-containing PDFs on, 249-250
- OG37-325 (cyclosporin G), 305
- 25(OH)D (25-hydroxycholecalciferol), serum, in long-term renal transplant recipients, 747, 749
- 1,25-(OH)₂D₃, *see* Calcitriol
- Older patients, *see* Elderly, the
- Once-a-day lisinopril and/or fosinopril, efficacy of, 901-902
- Oncotic pressure, role of, in FSGS, 147-152
- Opinion polls on ethical problems related to donor issues, 4:A4, 4:A10
- Opportunistic infections in renal transplantation, 754-758
- Oral Fe (iron), Fe management in ESRD patients on HD and on rHuEPO with, 325-326
- Oral glyburide in NIDDM patients with and without ESRD, pharmacokinetics of, 907-911
- Ornithine in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446
- Osmolarity of glucose polymer-containing PDFs, 247
- Osteocalcin, serum, and high-bone turnover and HPT in normocalcemic long-term renal transplant recipients, 746-753
- Osteodystrophy, renal, *see* Bone disease
- Outcome
 of ANCA-associated vasculitis following renal transplantation, 96-102
 of ARF, *see* Acute renal failure, management and outcome of
 of calcitriol pulses in advanced secondary HPT patients on HD, 4:A1, 4:A6-A7
 of ESRD with HIVAN, HD and, 549-552; *see also* Mortality of HD patients
 of exit-site povidone-iodine ointment in prevention of PD-related infections, 766
 IgAN, *see* Outcome, IgAN
 of IMN in the elderly, 202, 203
 of long-term HD vascular access with tunnelled permanent venous catheters, 4:A2, 4:A16
 of multidisciplinary predialysis interventions, 533-540
 of renal transplant recipients with thyroid cancer, 4:A4, 4:A14
 of surgical therapy of IRD, 179-181
 of *Xanthomonas maltophilia* peritonitis, 92
see also Patient survival; Prognosis; Renal allograft survival and specific conditions

- Outcome, IgAN, 529-530
 histologic subclassification and, 831-837
 indicators of patient survival, 840
 see also Prognosis, IgAN; Renal survival in IgAN
- Oxidants in toxic ARF, 465-477
 CsA and, 474-475
 gentamicin and, 466-468
 glycerol and, 468-474
- Oxidized low-density lipoproteins (LDLs), effects of, on mesangial cell proliferation, 919-930
- Oxygen (O₂)
 saturation of, in upper extremity with AV fistula before and after HD, pulse oxymetry of, 230-232
 see also Free radicals; Oxidants in toxic ARF
- Oxygenase, heme-, in glycerol-induced ARF, 473-474
- Oxymetry, pulse, of O₂ saturation in upper extremity with AV fistula before and after HD, 230-232
- P (phosphorus)
 in HPT, *see* P in HPT
 in hypokalemic metabolic alkalosis with hypomagnesuric hypermagnesemia and severe hypocalciuria, 108
 serum, *see* Serum P
- P (phosphorus) in HPT
 dietary, in secondary HPT with CRF, 496-502
 with hypercalcemia and hypophosphatemia, conventional Ca-containing dialysis solutions enriched with, 288-290
- PCO₂ (carbon dioxide partial pressure) in alkaline urine in tubular acidosis, 138-139, 141
- Paclitaxel (Taxol), effects of, on progression of PKD, 435-444
- Page kidney (constrictive perinephritis), hypertension secondary to, 620-623
- Painful hand, pulse oxymetry of O₂ saturation in, with AV fistula before and after HD, 230-232
- P-ANCAs, *see* Perinuclear antineutrophil cytoplasmic antibodies
- Paracentesis, described, 392
- Paradoxical cerebral air embolism due to central venous catheter, 453-455
- Parathormone, influence of, on ambulatory BP in CAPD patients, HD patients, and renal transplant recipients, 593-600
- Parathyroid hormone (PTH)
 plasma, in nonacidotic proximal tubulopathy with hypercalciuria, 493
 see also Hyperparathyroidism; Parathyroid hormone in CRF and/or ESRD patients; Serum parathyroid hormone
- Parathyroid hormone (PTH) in CRF and/or ESRD patients
 effects of multidisciplinary predialysis interventions on, 536
 on HD, 57, 240
 screening for intact, prior to starting rHuEPO therapy, 652
- Parathyroidectomy for secondary HPT in HD patients, biochemistry following, 759-762
- Parenchymal renal disease in chronic HD patients, residual renal function preservation with PS dialyzers and, 581
- Parenteral Fe (iron) for ESRD patients on HD and on rHuEPO, 326-329
- Parenteral nutrition
 in ARF management, 795
 intradialytic, effect of, on Ku/V, 4:A2, 4:A12-A13
- Passive Heymann nephritis (PHN), renoprotective properties of lisinopril in, 254-264
- Pathology, pathogenesis, and pathophysiology
 of IgA nephropathy, hemorrhheological alterations in, 4:A3, 4:A14
 of IRD, 169-171
 see also specific conditions
- Patient attitudes toward financial incentives for kidney donation, 410-418
- Patient characteristics, *see* Age; Body mass index; Body weight; Educational status; Employment status; Marital status; Race and ethnicity; Sex
- Patient education on multidisciplinary predialysis interventions, 533-540
- Patient survival
 with HCV-positive ESRD, effects of renal transplantation on, 608-614
 with IgAN, indicators of, 840
 with IRD, 182-183
 with renal transplantation, CMV infection effects on, 428-434
 see also Patient survival on HD
- Patient survival on HD
 with ESRD and HIVAN, 549-552
 or PD, prealbumin as predictor of, 4:A1, 4:A5-A6
- Pauci-immune segmental necrotizing glomerulonephritis (GN), P-ANCA-associated, membranous lupus nephritis with, 119-124
- PCR, *see* Protein catabolic rate on HD
- PD, *see* Peritoneal dialysis
- PDE (peritoneal dialysis effluent), cell population in, in stable CAPD patients, 699-705
- PDFs, *see* Peritoneal dialysis fluids
- PDGF (platelet-derived growth factor) A and B, and Lp effects on mesangial cell proliferation, 922-924
- Pediatric conditions, *see* Children
- Peptide
 atrial natriuretic, postural hemodilution in nephrotic edema and, 628
 HLA-derived, as immunosuppressants, 311-312
 see also specific peptides
- Percutaneous mechanical thrombectomy, AV fistula salvage with, 4:A1, 4:A9
- Percutaneous transluminal renal angioplasty (PTRA)
 of IRD, 180-181
 SCr following, in elderly patients with RAS, 4:A4, 4:A11
- Perfusion pressure, critical renal, IRD and, 169
- Perinephritis, constrictive, hypertension secondary to, 620-623
- Perinuclear antineutrophil cytoplasmic antibodies (P-ANCAs)
 membranous lupus nephritis associated with, pauci-immune segmental necrotizing GN with, 119-124
 vasculitis associated with, following renal transplantation, 96-102
- Peripheral arteriovenous (AV) versus central venovenous (CVV) vascular access, 479-489
 dialysis delivery with, *see* Dialysis delivery with peripheral AV versus CVV access

- dialyzer blood flow and, 486-487
 recirculation in, *see* Recirculation in peripheral AV versus CVV access
 venovenous disequilibrium and regional blood flow model in, *see* Regional blood flow model in peripheral AV versus CVV access; Venovenous disequilibrium in peripheral AV versus CVV access
- Peripheral neuropathy, primary hyperoxaluria with renal failure, livedo reticularis, and retinopathy, 947-952
- Peripheral vein recirculation method, defined, 488
- Peritoneal dialysis (PD)
 for ARF with HUS, pleural effusion complicating, 4:A1, 4:A6
 infections related to, *see* Infections, PD-related
see also Continuous ambulatory peritoneal dialysis; Peritoneal dialysis for CRF and/or ESRD; Peritoneal dialysis effluent; Peritoneal dialysis fluids
- Peritoneal dialysis (PD) for CRF and/or ESRD
 Ca and phosphate metabolism in, *see* Ca and phosphate metabolism management in CRF and/or ESRD
 early mortality in patients starting, 214-222
 prealbumin as predictor of survival on, 4:A1, 4:A5-A6
 quality of life 3 months after start of, 576-583
see also Continuous ambulatory peritoneal dialysis for CRF and/or ESRD; Dialysis for CRF and/or ESRD
- Peritoneal dialysis effluent (PDE), cell population in, in stable CAPD patients, 699-705
- Peritoneal dialysis fluids (PDFs)
 effects of, on mesothelial cells, 404-409
 effects of glucose polymer-containing, on phagocytic activity, 246-253
- Peritoneal transport parameters, cancer antigen 125 and dialysate cell population in stable CAPD patients and, 699-705
- Peritonitis on CAPD, 706-719
 acute, NO pathway and amino acids in, 712-719
 catheter infections and, 706-711
 effects of previous, on peritoneal transport, 702
 exit-site povidone-iodine ointment in prevention of, 763-768
 SEP, surgery of, 456-460
Xanthomonas maltophilia peritonitis, 91-95
- Permanent venous catheters, tunnelled, for long-term HD vascular access, 4:A2, 4:A16
- Persistent bicarbonaturia in tubular acidosis, 144
- PH, *see* Primary hyperoxaluria; Primary hyperoxaluria type 1 pH
 of glucose polymer-containing PDFs, 249-251
 urinary, in tubular acidosis, 139, 141
- Phagocytic activity
 effects of glucose polymer-containing PDFs on, 246-253
 rHuEPO effects on lymphocyte phenotyping and, in HD patients, 866-870
- Pharmacokinetics of oral glyburide in NIDDM patients with and without ESRD, 907-911
- Phenotype
 enzymic, lack of relationship between genotype, severity of PH1 and, 36-44
 rHuEPO effects on lymphocyte phenotyping and phagocyte activity in HD patients, 866-870
- Phenylalanine in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446
- PHN (passive Heymann nephritis), renoprotective properties of lisinopril in, 254-264
- Phosphatase, *see* Alkaline phosphatase
- Phosphate
 in ESRD, 536, 695-696
 phosphate wasting and high-bone turnover and HPT in normocalcemic long-term renal transplant recipients, 746-753
 RenaGel as binder of, *see* RenaGel
 serum, *see* Serum phosphate
see also Ca and phosphate metabolism management in CRF and/or ESRD; Diphosphate; Hyperphosphatemia; Hyperphosphaturia; Hypophosphatemia; P
- Phosphorus, *see* P
- Physicians, *see* Nephrology, future aspects of; Renal physicians, supply of
- Physiology of tubular acidosis, 137-140
- PKD, *see* Autosomal dominant polycystic kidney disease; Polycystic kidney disease, CRF and/or ESRD and; Progression of PKD
- Plasma albumin in ascitic patients, 394
- Plasma calcitriol (1,25-dihydroxyvitamin D₃) in nonacidotic proximal tubulopathy with hypercalciuria, 493
- Plasma creatinine (Cr) in ascitic patients, 394
- Plasma flow, *see* Renal plasma flow in HTN
- Plasma K (potassium) in ascitic patients, 394
- Plasma Na (sodium) in ascitic patients, 394
- Plasma parathyroid hormone (PTH) in nonacidotic proximal tubulopathy with hypercalciuria, 493
- Plasma proteins
 in ascitic patients, 394
 total, in IgAN, 530
- Platelet(s)
 deposition of, on PTFE graft fistulas, effects of aspirin or ticlopidine on, 560-564
 function of, in FSGS and MCNS, 4:A3, 4:A5
see also Platelet count
- Platelet count
 in ARF due to postinfectious nephritis in pregnancy, 274
 in ascitic patients, 394
 in ESRD with HIVAN, 551
- Platelet-derived growth factor (PDGF) A and B, and Lp effects on mesangial cell proliferation, 922-924
- Pleural effusion complicating PD of ARF with HUS, 4:A1, 4:A6
- PMNLs (polymorphonuclear neutrophils), *see* Neutrophil(s)
- Poly[allylamine hydrochloride], *see* RenaGel
- Polycystic disease, *see* Autosomal dominant polycystic kidney disease; Autosomal dominant polycystic liver disease; Polycystic kidney disease, CRF and/or ESRD and; Progression of PKD
- Polycystic kidney disease (PKD), CRF and/or ESRD and in chronic HD patients, residual renal function preservation using PS dialyzers and, 581
 early death prediction and in patients starting dialysis, 216
 with HCV infection, 610, 611
 with HPT, 863
 and ketoconazole effects on CRF progression, 505, 507
 quality of life and, 586, 588, 891
 rHuEPO therapy and, 653
- Polycystic liver disease, autosomal dominant, portal hyper-

- tension and bleeding esophageal varices due to, 4:A3, 4:A18
- Polymorphonuclear neutrophils, *see* Neutrophil(s)
- Polyomavirus, interstitial nephritis induced by, in renal transplant recipients, 754-758
- Polyphenols, anti-oxygen free radicals of tea, for CRF, 4:A3, 4:A7
- Polysulfone (PS) dialyzers, preservation of residual renal function with cellulose acetate dialyzers and, in ESRD patients on CAPD, compared, 576-583
- Polytetrafluoroethylene (PTFE) graft fistulas, effects of aspirin or ticlopidine on platelet deposition on, 560-564
- Population growth, and recent trends in supply of renal physicians, 784
- Portal hypertension, bleeding esophageal varices and, due to ADPKD, 4:A3, 4:A18
- Postdialytic symptoms, Na ramping and, 672, 673
- Postural hemodilution in nephrotic edema, as cause of hemorrhage following renal biopsy, 627-630
- Potassium, *see* K
- Povidone-iodine ointment, exit-site, in prevention of PD-related infections, 763-768
- Practice of nephrology, future, 638-639
- Prealbumin, as predictor of survival in PD and HD, 4:A1, 4:A5-A6
- Predialysis patients, 533-548
CV effects of rHuEPO in, 541-548
multidisciplinary interventions with, 533-540
- Prednisone
effects of ketoconazole and low-dose, on progression of CRF, 503-513
for HIV-associated glomerulopathy, 4:A3, 4:A12
- Preeclamptic nephropathy, ET-1 in, 345-354
- Preexisting vascular disease in diabetic renal transplant candidates, 602
- Pregnancy, ARF due to postinfectious GN during, 273-279
- Pressure
carbon dioxide partial, in alkaline urine in tubular acidosis, 138-139, 141
critical renal perfusion, IRD and, 169
oncotic, in FSGS, 147-152
see also Blood pressure
- Prevalence
of aPLs in SLE, 358
of HPT, 863
of IRD, 175
of RAS, *see* Prevalence of RAS
see also *specific conditions*
- Prevalence of RAS
of atherosclerotic RAS in IRD, 171-173; *see also* Ischemic renal disease
in myocardial infarction, 733-738
- Prevention of PD-related infections with exit-site povidone-iodine ointment, 763-768
- Previous amputation in diabetic renal transplant candidates, 605, 606
- Previous peritonitis on CAPD, effects of, on peritoneal transport, 702
- Primary amyloidosis, syncope with, 4:A3, 4:A18
- Primary disease
and attitudes toward financial incentives for kidney donation, 412, 414
in CRF and/or ESRD, *see* Primary disease in CRF and/or ESRD
and dialysate Na effects on hypertension, 384
and elevated serum creatinine level, 364
in inner-city renal transplant recipients, 883
and renal allograft survival in hypertensive African American recipients, 420
see also *specific conditions*
- Primary disease in CRF and/or ESRD
and anemia screening prior to starting rHuEPO therapy, 653
and early death prediction in patients starting dialysis, 216
in HCV-positive ESRD, 610, 611
with HPT, 863
and hypoalbuminemia on HD, 660
in in-center HD patients, 854, 856
preservation of residual renal function and, 578, 581
and quality of life 3 months after start of chronic HD and/or PD, 586, 588, 589
see also *specific conditions*
- Primary glomerulonephritis (GN), corticosteroid effects on lymphocytes in, 4:A3, 4:A17
- Primary hyperoxaluria (PH) with renal failure, livedo reticularis, retinopathy, and peripheral neuropathy, 947-952
- Primary hyperoxaluria type 1 (PH1), vertical pattern of inheritance of, 36-44
- Primary renal disease in CRF, quality of life and, 891
- Primary specialties among renal physicians, 782-783
- PRL (prolactin), rHuEPO effects on, 4:A2, 4:A11-A12
- Prognosis
of chronic HD patients, serum cardiac troponin I and cardiac troponin T, 399-403
of GN with proteinuria, LMW proteins and, 27-35
IgAN, *see* Prognosis, IgAN
see also Outcome
- Prognosis, IgAN
prognosis of progressive renal disease in IgAN, histologic grading system and, 953-958
renal biopsy data and, 818-819
see also Outcome, IgAN
- Progression of (and to) CRF and/or ESRD
early detection and management of hypertensive and diabetic renal disease in hospitalized patients preventing, 368-375
effects of ketoconazole and low-dose prednisone on, 503-513
of IgAN, *see* Progression of (and to) CRF and/or ESRD, IgAN
of proteinuric GN, LMW proteins and, 27-35
- Progression of (and to) CRF and/or ESRD, IgAN
histologic grading system and, 953-958
histologic IgAN subclassification and, 829-842
- Progression of PKD
of ADPKD, sex and effects of gonadal hormones on, 265-272
effects of ketoconazole and low-dose prednisone on, 503-513
paclitaxel effects on, 435-444
- Progressive renal failure, rapidly, in fMF with light chain deposition disease, 942-946
- Projected supply of renal physicians, 786-789

- Prolactin (PRL), rHuEPO effects on, 4:A2, 4:A11-A12
- Proliferative glomerulonephritis, *see* Membranoproliferative glomerulonephritis
- Proliferative lupus nephritis, diffuse, PS deficiency and, 931-935
- Proline in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446
- Protein(s)
- cortical and medullary membrane, K depletion effects on, 4:A4, 4:A8-A9
 - C-reactive, *see* C-reactive protein in CRF and/or ESRD patients on HD
 - dietary, *see* Dietary protein intake
 - fusion, costimulatory signals and, in immunosuppression, 311
 - LMW, in GN with proteinuria, clinical significance and prognostic value of, 27-35
 - plasma, *see* Plasma proteins
 - total, *see* Total proteins
 - see also* Protein catabolic rate on HD; Protein S deficiency; Proteinuria
- Protein catabolic rate (PCR) on HD
- and Ab response to HBV vaccine, 240
 - normalized, 3 months after start of chronic HD and/or PD, 586, 589
- Protein S (PS) deficiency, DPLN and, 931-935
- Proteinuria
- in arteriolar sclerosis, 914
 - in CRF, *see* Proteinuria in CRF
 - in FSGS with NS in cholesterol atheroembolism, 334-344
 - in GN, SDS-PAGE in characterization of, 27-35
 - in hospitalized hypertensive and diabetic patients, 370, 371
 - in IgAN, 527, 528, 530
 - in IMN, 201, 202
 - influence of dietary NaCl on antiproteinuric effects of Ca channel blockers, 800-805
 - in membranous nephropathy, 116
 - myocardial infarction, renal artery stenosis and, 734
 - in nonacidotic proximal tubulopathy with hypercalciuria, 493
 - secondary to bilateral renal vein thrombosis, systemic thrombolytic therapy of, 615-619
 - see also* Albuminuria
- Proteinuria in CRF
- ketoconazole plus low-dose prednisone effects on, 503-513
 - and rHuEPO in predialysis CRF patients, 543
- Proton-pump inhibitor, amoxicillin and, in eradication of *H pylori* in ESRD patients on dialysis, 86-90
- Protoporphyrin, zinc, in ESRD, 325
- Proximal tubular acidosis, isolated, 143
- Proximal tubular cells, isoflurane effects on energetics of, 4:A1, 4:A12
- Proximal tubules
- fluid and electrolyte transport by, ET effects on, 8-10
 - fractional solute reabsorption by, in hypokalemic metabolic alkalosis with hypomagnesuric hypermagnesemia and severe hypocalciuria, 106-114
 - see also* Proximal tubulopathy and entries beginning with terms: Proximal tubular
- Proximal tubulopathy, nonacidotic autosomal dominant, 490-495
- PS (polysulfone) dialyzers, preservation of residual renal function with cellulose acetate dialyzers and, in ESRD patients on CAPD, compared, 576-583
- PS (protein S) deficiency, DPLN and, 931-935
- Pseudodominant (vertical) pattern of PH1 inheritance, 36-44
- Pseudopulmonary embolism in heparin-induced thrombocytopenia and thrombosis, 449-452
- PTFE (polytetrafluoroethylene) graft fistulas, effects of aspirin or ticlopidine on platelet deposition on, 560-564
- PTH, *see* Parathyroid hormone
- PTRA, *see* Percutaneous transluminal renal angioplasty
- Pulmonary mucormycosis in diabetic renal transplant recipients, 461-464
- Pulse calcitriol (1,25-dihydroxyvitamin D₃) in advanced secondary HPT, 4:A1, 4:A6-A7
- Pulse oxymetry of O₂ saturation in upper extremity with AV fistula before and after HD, 230-232
- Purpura, *see* Henoch-Schönlein purpura
- Pyelonephritis, chronic, ESRD and, 660
- Quality of care
- early detection and management of hypertensive and diabetic renal disease in hospitalized patients and, 368-375
 - improvement in delivery of in-center HD for ESRD as indicator of, 851-861
- Quality of life of CRF and/or ESRD patients
- MDRD study of, 888-896
 - 3 months after start of chronic HD and/or PD, 584-592
- Quality of Well-Being Scale (QWB) used in MDRD study of CRF patients, 888-896
- Race and ethnicity
- and attitudes toward financial incentives for kidney donation, 412, 414
 - of CRF and/or ESRD patients on dialysis, 216, 686; *see also* Race and ethnicity of CRF and/or ESRD patients on CAPD and/or HD
 - and familial clustering of ESRD with lupus nephritis and, 729-732
 - hypertension and, *see* Hypertension, race and
 - of ICGN patients with HIV and HCV infections, 516
 - of IgAN patients, 201, 526-532
 - of IMN patients, 201
 - of inner-city renal transplant recipients, 882
 - and renal response to chronic fosinopril and/or lisinopril therapy in older hypertensive patients with chronic renal insufficiency, 897-906
 - sex and, and risk of ESRD with diabetic nephropathy, 4:A3, 4:A19-A20
 - SLC associated with insulin resistance and albuminuria and, 45-53
 - of SLE patients, aPLs and, 357
 - and vasectomy as risk factor for urolithiasis, 209
- Race and ethnicity of CRF and/or ESRD patients on CAPD and/or HD
- ABPM and, 679
 - with HIVAN, 550
 - with HPT, 863
 - of hyperphosphatemic CRF patients, 68
 - and hypoalbuminemia on HD, 660
 - on in-center HD, 854, 856

- positive for HCV, 610, 611
- Radicals, *see* Free radicals
- Radiopaque dye nephropathy, ETs in, 13-14
- Rapamycin (sirolimus), 307
- Rapidly progressive renal failure in fMf with light chain deposition disease, 942-946
- RAS, *see* Renal artery stenosis
- Rationing of dialysis for ESRD, early death and, 214-222
- RBF, *see* Renal blood flow
- Reactive oxygen metabolites, *see* Oxidants in toxic ARF
- Recirculation, vascular access
- relationship of, to BF, 223-229
 - urea sampling measuring, in HD of ARF, 4:A1, 4:A10-A11
 - see also* Recirculation in peripheral AV versus CVV access
- Recirculation in peripheral AV versus CVV access, 479-484
- AV disequilibrium, cardiopulmonary recirculation, dialysis delivery and, 483-484
- in CVV access, 479-481
 - with CVV catheters, 483
 - with femoral vein catheters, 480
 - line reversal and, 482-483
 - in peripheral AV access, 480-482
- Recombinant human erythropoietin (rHuEPO)
- cardiovascular effects of, in predialysis CRF patients, 541-548
 - reproductive and gynecologic issues in women on dialysis, 686; *see also* Recombinant human erythropoietin for CRF and/or ESRD patients on CAPD and/or HD
- Recombinant human erythropoietin (rHuEPO) for CRF and/or ESRD patients on CAPD and/or HD
- ABPM of CAPD patients, 679
 - cost-effectiveness of anemia screening prior to starting, 651-657
 - effects of, on Ab response to HBV vaccine, 241
 - effects of, on lymphocyte phenotyping and phagocyte activity, 866-870
 - effects of, on PRL levels, hypogonadism, and bone density, 4:A2, 4:A11-A12
 - Fe and, *see* Fe in CRF and/or ESRD patients on HD and on rHuEPO therapy
 - interaction between enalapril and, in chronic HD patients, 4:A2, 4:A18
 - resistance to, *see* Resistance to rHuEPO therapy
- Recurrence
- of ANCA-associated vasculitis following renal transplantation, 96-102
 - of IgAN with IgA ANCA following renal transplantation, 125-131
 - of NS, minimal change NS, FSGS, C1q nephropathy and, 966-970
- Red cell ferritin in ESRD, 323
- Regional blood flow (BF) model in peripheral AV versus CVV access
- defined, 488
 - venovenous disequilibrium and, 484-486
- Regional databank on IgAN renal biopsy, 818
- Rehabilitation of chronic HD patients, 4:A2, 4:A21
- Rejection, acute renal graft, IL-8 expression following renal transplantation and, 871-880
- Relapse, *see* Recurrence
- Relatives, *see* Families
- Relaxation, MC, in GFR regulation, 975-976
- RenaGel (poly[allylamine hydrochloride])
- effects of, on serum P and PTH in HD patients, 4:A1, 4:A6
 - as noncalcemic phosphate binder for hyperphosphatemia in CRF, 66-71
- Renal allograft rejection, IL-8 expression following renal transplantation and, 871-880
- Renal allograft survival, 419-434
- CMV infection effects on, 428-434
 - relationship between hypertension and, race and, 419-427
- Renal angioplasty, *see* Percutaneous transluminal renal angioplasty
- Renal artery stenosis (RAS)
- in elderly patients, SCr following PTR of, 4:A4, 4:A11
 - prevalence of, *see* Prevalence of RAS
 - unilateral FSGS and, 936-941
- Renal artery stents for IRD, 181-182
- Renal biopsy
- hemorrhage following, postural hemodilution in nephrotic edema as cause of, 627-630
 - in ICGN with HIV and HCV infections, 516, 517
 - in IgAN, *see* Renal biopsy in IgAN
 - in nephrotic syndrome with hematuria and renal insufficiency, 806-810
 - of preeclamptic nephropathy, 345-354
 - of relapsing NS, 966-967
 - see also* Histology and histopathology and specific conditions
- Renal biopsy in IgAN
- indication for, 527
 - see also* Histology and histopathology, IgAN; Renal biopsy data on IgAN, management of
- Renal biopsy data on IgAN, management of, 817-828
- administrative issues related to, 823-824
 - and clinicopathologic correlations from IgAN database of Mayo Nephrology Collaborative Group, 820-821
 - conclusions and recommendations on, 824-826
 - and histologic gradation of biopsy specimens, 821-822
 - IgAN prognosis and, 818-819
 - issues related to database development in, 822-823
 - progress on regional databank and, 818
 - scoring systems and, 819-820, 825
- Renal blood flow (RBF)
- of hypertensive patients, endogenous EPO and, 377
 - see also* Renal blood flow, ET-1 and
- Renal blood flow (RBF), ET-1 and, 4
- in ischemic renal failure, 12
 - in toxin-related renal injury, 14
- Renal cortical mitochondria
- gentamicin effects on production of H₂O₂ by, 467
 - gentamicin-induced Fe mobilization from, 467-468
- Renal disease and disorders
- effects, on mesangial cell tone, GFR regulation and, 976-977
 - ETs in, 12-17
 - see also* specific conditions
- Renal failure, 942-952
- primary hyperoxaluria with livedo reticularis, retinopathy, and peripheral neuropathy, 947-952
 - rapidly progressive, in fMf with light chain deposition disease, 942-946

- severe hyperphosphatemia following phosphate administration for bowel preparation in patients with, 103-105
see also Acute renal failure; Chronic renal failure; Ischemic renal failure
- Renal function
 bone density and metabolism with reduced, 4:A3, 4:A9
 in CRF and/or ESRD, *see* Renal function in CRF and/or ESRD
 with IgAN, 527
 with IRD, surgical retrieval of, 179-180
 lisinopril effects on, in membranous nephropathy, 257-258
see also Renal insufficiency; Renal sufficiency *specific aspects of renal function and specific conditions*
- Renal function in CRF and/or ESRD
 on CAPD, preservation of residual with polysulfone dialyzers in, 576-583
 3 months after start of chronic HD and/or PD, 586, 588-589
- Renal hemodynamics
 monitoring of, in ARF management, 794
see also Glomerular filtration rate; Hyperfiltration; Renal blood flow; Renal plasma flow in HTN
- Renal injury, toxin-related, ETs in, 12-14
- Renal insufficiency
 chronic, *see* Chronic renal insufficiency in the elderly
 myocardial infarction, renal artery stenosis and, 734
 in PKD, paclitaxel effects on, 435-444
- Renal osteodystrophy, *see* Bone disease
- Renal perfusion pressure, critical, IRD and, 169
- Renal physicians, supply of, 781-792
 AMA Physician Masterfile and, 781-782
 current supply, 782-784
 and future utilization of nephrology services, 789-790
 projected supply, 786-789
 recent trends in, 784-785
- Renal plasma flow (RPF) in HTN
 in elderly hypertensive patients with chronic renal insufficiency, effects of chronic ACE inhibition on, 900-902
 endogenous EPO and, 377
- Renal replacement therapy (RRT)
 continuous, for ARF, 796
see also Dialysis; Renal transplantation
- Renal resistance vessels, ETs in, 4-6
- Renal response to chronic foscipril and/or lisinopril therapy
 in older hypertensive patients with chronic renal insufficiency, racial differences in, 897-906
- Renal sufficiency, nephrotic syndrome with hematuria and, renal biopsy of, 806-810
- Renal survival in IgAN, 529-530
 histologic subclassification and, 833
- Renal transplantation, 593-614
 ABPM in recipients of, 593-600
 ANCA's following, *see* Antineutrophil cytoplasmic antibodies following renal transplantation
 changes in eating behavior following, 691-698
 CMV infection effects on survival with, 428-434
 in diabetic patients, *see* Renal transplantation in diabetic patients
 effects of, on HCV-positive ESRD patient survival, 608-614
 for fMF with light chain deposition disease, 942-946
 IL-8 expression following, as predictor of rejection, 871-880
 normocalcemic long-term recipients of, high-bone turnover and HPT in, 746-753
 in patients with malignant disease, *see* Renal transplantation in patients with malignant disease
 polyomavirus-induced interstitial nephritis in recipients of, 754-758
 for primary hyperoxaluria with renal failure, livedo reticularis, retinopathy, and peripheral neuropathy, 947-952
 unemployment among inner-city recipients of, 881-887
see also Clinical studies and trials of new immunosuppressive agent(s); Donors
- Renal transplantation in diabetic patients, 420
 atherosclerotic vascular complications in, 601-607
 pulmonary mucormycosis in, 461-464
- Renal transplantation in patients with malignant disease
 retransplantation, 4:A4, 4:A15-A16
 with thyroid cancer, 4:A4, 4:A14
 with transitional cell carcinoma, 4:A4, 4:A15
- Renal tubules, *see* Tubules
- Renal ultrasound for elevated serum creatinine level, 362-367
- Renal vascular resistance, chronic lisinopril and/or foscipril effects on, 901
- Renal vasculature, ET-1 in, 4-6
 ET-1-induced constriction of, 5-6
 ET-1 production by, 4
 ET-1 receptors in, 4-5
- Renal vein thrombosis (RVT), bilateral, systemic thrombolytic therapy of proteinuria secondary to, 615-619
- Renal weight in ADPKD, 267, 268
- Renal work notion, history of, 777-780
- Renin, postural hemodilution in nephrotic edema and, 628
- Renin-angiotensin system, expression of components of, in diabetes, 154-156
- Renoprotective properties of lisinopril in membranous nephropathy, 254-264
- Reproduction by women on dialysis, 685-690
- Research, future nephrology, 637
- Residual glomerular filtration rate (rGFR) 3 months after start of chronic HD and/or PD for CRF and/or ESRD, 586, 589
- Residual renal function, polysulfone dialyzers and preservation of, in ESRD patients on CAPD, 576-583
- Resistance, *see* Insulin resistance; Resistance to rHuEPO therapy
- Resistance to rHuEPO therapy
 causes of, 320
 C-reactive protein as predictor of, 565-568
 in ESRD with heterozygous hemoglobinopathy J-Meining, 769-772
- Respiratory distress, acute, in heparin-induced thrombocytopenia and thrombosis, 449-452
- Retinopathy, primary hyperoxaluria with renal failure, livedo reticularis, and peripheral neuropathy, 947-952
- Retransplantation in patient with malignant disease, 4:A4, 4:A15-A16
- Revascularization, surgical, in dialysis-dependent IRD, 180
 rGFR (residual glomerular filtration rate) 3 months after start

- of chronic HD and/or PD for CRF and/or ESRD, 586, 589
- Rheumatoid arthritis in relatives of lupus nephritis patients, 731
- rHuEPO, *see* Recombinant human erythropoietin
- Ribonucleic acid (RNA)
 - ECM messenger, effects of lisinopril on expression of, in PHN, 259
 - HCV, in ICGN with HIV and HCV infections, 516
- Rickets, nonacidotic proximal tubulopathy compared with, 493
- Risk factor(s)
 - for atherosclerotic RAS in IRD, 173
 - for CRF and/or ESRD, race, sex, diabetic nephropathy and, 4:A3, 4:A19-A20
 - for hospitalization of HD patients, 4:A1, 4:A7-A8
 - for IgAN, 526-532
 - Lp(a) and other cardiovascular, in CRF and/or ESRD patients on dialysis, 4:A2, 4:A13
 - vasectomy as, for urolithiasis, 207-213
 - see also specific risk factors*
- RNA, *see* Ribonucleic acid
- RPF, *see* Renal plasma flow in HTN
- RRT, *see* Renal replacement therapy
- RS-61443 (mycophenolate mofetil), 309-310
- RVT (renal vein thrombosis), bilateral, proteinuria secondary to, systemic thrombolytic therapy of, 615-619
- S aureus (Staphylococcus aureus)* carriers, PD-related infections in nasal, 763-768
- SAA (serum amyloid A), and albumin concentrations in ESRD patients on HD, 658-668
- Salt, dietary, influence of, on antiproteinuric effects of Ca channel blockers, 800-805
- Saphenous vein endothelial cells, human, serum factors inhibiting adherence of monocytes and granulocytes to, during HD, 78-85
- SBP (systolic blood pressure), *see* Blood pressure
- SCL-90R (Symptom Checklist-90R) used in MDRD study of CRF patients, 888-896
- Sclerosing encapsulating peritonitis (SEP), surgery of, 456-460
- Sclerosis
 - myofibroblasts and arteriolar, in diabetic nephropathy, 912-918
 - see also* Glomerulosclerosis; Nephrosclerosis; Sclerosing encapsulating peritonitis and entries beginning with term: Atherosclerotic
- Scoring systems for IgAN, 819-820, 825
- SCr, *see* Serum creatinine
- Screening, anemia, prior to starting rHuEPO therapy of ESRD patients, cost-effectiveness of, 651-657
- SDS-PAGE (sodium dodecyl sulphate-polyacrylamide gel electrophoresis), proteinuria in GN characterized with, 27-35
- Secondary hyperparathyroidism, *see* Calcitriol for secondary HPT; Hemodialysis for secondary HPT
- Secondary specialties among renal physicians, 782-783
- Segmental glomerulosclerosis, *see* Focal segmental glomerulosclerosis
- Segmental necrotizing glomerulonephritis (GN), P-ANCA-associated pauci-immune, membranous lupus nephritis with, 119-124
- Selectin, and monocyte and granulocyte adherence to HSVECs during HD, 78-85
- Self-care continuous ambulatory peritoneal dialysis (CAPD), HHD for, patients trained in, 4:A1, 4:A10
- SEP (sclerosing encapsulating peritonitis), surgery of, 456-460
- Serine in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446
- Sertraline hydrochloride, effect of, on HD hypotension, 4:A1, 4:A8
- Serum albumin
 - in ARF due to postinfectious GN during pregnancy, 274
 - in CRF and/or ESRD, *see* Serum albumin in CRF and/or ESRD
 - in ICGN with HIV and HCV infections, 516
 - in IMN, 201-203
 - in long-term renal transplant recipients, 747, 749
 - in membranous nephropathy, 116
 - and quality of life in chronic dialysis patients, 589
- Serum albumin in CRF and/or ESRD
 - with HIVAN, 549-552
 - quality of life and, 891
 - rHuEPO resistance and, 567
 - with SLE, 731
 - starting dialysis, 219
 - 3 months after start of chronic HD and/or PD, 586, 589
- Serum aluminum (Al) in CRF and/or ESRD
 - rHuEPO resistance and, 567
 - screening for concentrations of, prior to starting rHuEPO therapy, 652
- Serum amyloid A (SAA), and albumin concentrations in ESRD patients on HD, 658-668
- Serum BUN (blood urea nitrogen) in ARF due to postinfectious nephritis in pregnancy, 274
- Serum Ca (calcium)
 - in hyperparathyroidic ESRD patients on HD, 862-865
 - nifedipine effects on, 234
 - total, in long-term renal transplant recipients, 747, 749
- Serum calcitriol [1,25-(OH)₂D₃] in long-term renal transplant recipients, 747, 749
- Serum cardiac troponin I (cTnI) and cardiac troponin T (cTnT), prognosis of chronic HD patients and, 399-403
- Serum Cl (chloride)
 - in ARF due to postinfectious GN during pregnancy, 274
 - effects of P-enriched conventional Ca-containing dialysis solution on, 289
- Serum creatinine (SCr)
 - in ARF due to postinfectious nephritis in pregnancy, 274
 - in arteriolar sclerosis, 914
 - in CRF and/or ESRD, 505, 551, 891
 - effects of antihypertensive therapy on, race and, 723
 - in elderly hypertensive patients with chronic renal insufficiency, effects of chronic ACE inhibition, 900
 - following PTRAs of elderly ischemic nephropathy patients, 4:A4, 4:A11
 - in FSGS with NS in CAE, 336
 - in hospitalized hypertensive diabetic patients, 370, 371
 - in ICGN with HIV and HCV infections, 516

- in IgAN, 530, 833
- in IMN, 201, 202
- P-enriched conventional Ca-containing dialysis solution effects on, 289
- in preeclampsia, 347
- in proteinuric GN, 29-31
- in renal transplant recipients, *see* Serum creatinine in renal transplant recipients
- renal ultrasound for elevated, 362-367
- in SLE, 731
- Serum creatinine (SCr) in renal transplant recipients
 - in long-term renal transplant recipients with high-bone turnover and HPT, 747, 749, 750
 - and renal allograft function in hypertensive recipients, race and, 423
- Serum factors inhibiting adherence of monocytes and granulocytes to human saphenous endothelial cells during HD, 78-85
- Serum Fe (iron), screening for, prior to starting rHuEPO therapy of ESRD patients, 652
- Serum ferritin in CRF and/or ESRD, 322-324
 - red cell, 324
 - rHuEPO resistance and, 567
- Serum gastrin following *H pylori* eradication in dialyzed ESRD patients, 87-88
- Serum glutamate pyruvate transaminase, *see* Alanine transaminase
- Serum glutamic-oxaloacetic transaminase, *see* Aspartate transaminase
- Serum H_2CO_3 (bicarbonate) in ESRD with HPT, 864
- Serum 25-hydroxycholecalciferol [25(OH)D] in long-term renal transplant recipients, 747, 749
- Serum K (potassium)
 - in ARF due to postinfectious GN during pregnancy, 274
 - effects of P-enriched conventional Ca-containing dialysis solution on, 289
 - in hypokalemic metabolic alkalosis with hypomagnesuric hypermagnesemia and severe hypocalciuria, 108
- Serum lipids, androgen effects on levels of, in chronic HD patients, 569-575
- Serum lipoprotein(a) [lp(a)], nandrolone decanoate effects on concentrations of, in chronic HD patients, 569-575
- Serum Mg (magnesium) in hypokalemic metabolic alkalosis with hypomagnesuric hypermagnesemia and severe hypocalciuria, 108
- Serum Na (sodium)
 - in ARF due to postinfectious GN during pregnancy, 274
 - effects of P-enriched conventional Ca-containing dialysis solution on, 289
- Serum osteocalcin, and high-bone turnover and HPT in normocalcemic long-term renal transplant recipients, 746-753
- Serum P (phosphorus)
 - in ESRD with HPT, 864
 - see also* Serum P in HD patients
- Serum P (phosphorus) in HD patients
 - nifedipine effects on, 234
 - RenaGel effects on, 4:A1, 4:A6
- Serum parathyroid hormone (PTH)
 - in HD, *see* Serum parathyroid hormone, HD and
 - in long-term renal transplant recipients, 747, 749
- Serum parathyroid hormone (PTH), HD and
 - in CRF patients, rHuEPO resistance and, 567
 - nifedipine effects on, 234
 - RenaGel effects on, 4:A1, 4:A6
- Serum phosphate
 - in hyperparathyroid ESRD patients on HD, 862-865
 - in long-term renal transplant recipients, 747, 749
- Serum transferrin in CRF patients on HD, rHuEPO resistance and, 567
- Serum urea nitrogen
 - in ADPKD, 267, 268
 - in CRF, 505
 - effects of P-enriched conventional Ca-containing dialysis solution on, 289
- Serum uric acid in ARF due to postinfectious GN during pregnancy, 274
- Severe hyperphosphatemia following phosphate administration for bowel preparation in renal failure patients, 103-105
- Severe hypertension (HTN) secondary to systemic entomophthoromycosis, 620-623
- Severe hypocalcemia and hypophosphatemia (hungry bone syndrome) following parathyroidectomy for secondary HPT in ESRD patients on HD, 759-762
- Severe hypocalciuria, hypokalemic metabolic alkalosis with hypomagnesuric hypermagnesemia and, 106-114
- Severe hypophosphatemia
 - isolated hyperphosphaturia and, with multiple myeloma, 445-448
 - severe hypocalcemia and, following parathyroidectomy for secondary HPT in ESRD patients on HD, 759-762
- Severity of disease
 - of PHI, lack of relationship between genotype and, 36-44
 - see also* entries beginning with term: Severe
- Sex
 - and attitudes toward financial incentives for kidney donation, 412, 414
 - body weight and, and nephrosclerosis, 4:A4, 4:A16
 - of children with biliary atresia, 189
 - of CRF and/or ESRD patients, 505, 731, 891; *see also* Sex of CRF and/or ESRD patients on CAPD and/or HD
 - of FSGS patients with NS in CAE, 336
 - and gonadal hormone effects on progression of ADPKD, 265-272
 - of hypertensive patients, 370, 384, 420
 - of ICGN patients with HIV and HCV infections, 516
 - of IgAN patients, 528, 533
 - of IMN patients, 201
 - of myocardial infarction patients with renal artery stenosis, 734
 - of NIDDM patients, 908
 - of primary amyloidosis patients presenting with syncope, 4:A3, 4:A18
 - race and, and risk of ESRD with diabetic nephropathy, 4:A3, 4:A19-A20
 - of renal physicians, 783, 785, 787, 789
 - of renal transplant recipients, *see* Sex of renal transplant recipients
 - of SLE patients, aPLs and, 357
 - see also* Women and specific conditions

- Sex of CRF and/or ESRD patients on CAPD and/or HD and Ab response to HBV vaccine, 240
 ABPM and, 594, 679
 and dialysate Na effects on hypertension, 384
 of dyslipidemic patients, 55
 and effects of exit-site povidone-iodine ointment on infections, 764
 having developed SLE 14 years after commencing HD, 631-632
 with HIVAN, 550
 with HPT, 863
 of hyperphosphatemic patients, 68
 on in-center HD, 854, 856
 on nifedipine therapy, 234
 positive for HCV, 610, 611
 preservation of residual renal function and, 578
 and quality of life 3 months after start of chronic HD, 586, 588
 and resistance to rHuEPO, 566
 starting dialysis, early death and, 216
- Sex of renal transplant recipients
 diabetic, atherosclerotic vascular complications and, 602, 605
 hypertensive, renal allograft survival and, 420
 of inner-city recipients, 882
 long-term recipients, high-bone turnover and HPT in, 747, 749, 750
- Sexuality, effects of dialysis for ESRD on women's, 685-690
- SGOT (serum glutamic-oxaloacetic transaminase), *see* Aspartate transaminase
- SGPT (serum glutamate pyruvate transaminase), *see* Alanine transaminase
- Short-bowel syndrome, calciphylaxis and, 773-776
- Short-term effects of antihypertensive therapy on GFR, race and, 720-728
- Silicon dual-lumen catheters, long-term vascular access for HD using, with guidewire replacement of catheters, 553-559
- Sirolimus (rapamycin), 307
- Sixth annual spring nephrology meetings (April 17-20, 1997), abstracts of, 4:A1-A21
- SKF-105685, 311
- Skin fibroblasts, collagen mRNA in, in IDDM nephropathy patients, 4:A4, 4:A20
- SLC (sodium-lithium countertransport) associated with insulin resistance and albuminuria in young African Americans, 45-53
- SLE, *see* Systemic lupus erythematosus
- Slow-flow/stop-flow recirculation method, defined, 488
- Smoking
 by CRF patients, quality of life and, 891
 by diabetic renal transplant candidates, atherosclerotic vascular complications and, 602
 by FSGS patients with NS in CAE, 336
 myocardial infarction, renal artery stenosis and, 734
 as risk factor for presence of atherosclerotic RAS in IRD, 173
- Sodium, *see* Na
- Sodium chloride (NaCl), dietary, influence of, on antiproteinuric effects of Ca channel blockers, 800-805
- Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), proteinuria in GN characterized with, 27-35
- Sodium-lithium countertransport (SLC) insulin resistance and albuminuria associated with, race and, 45-53
- Soft tissue calcification due to Ca and phosphate overload in ESRD, 645-646
- Soluble transferrin receptor in ESRD, 325
- Specialties, primary and secondary, among renal physicians, 782-783
- Staphylococcus aureus* (*S aureus*) carriers, PD-related infections in nasal, 763-768
- Stenosis, *see* Renal artery stenosis
- Stents, renal artery, for IRD, 181-182
- Steroids, *see* Corticosteroids
- Stones, *see* Nephrolithiasis; Urolithiasis
- Subclassification, histologic IgAN, 829-842
- Superoxide (O₂-), effects of glucose polymer-containing PDFs on, 249-250
- Supplementation, Ca and/or vitamin D, in HPT, 863
- Supply of renal physicians, *see* Renal physicians, supply of
- Surgery
 of IRD, 179-182
 parathyroidectomy for secondary HPT in HD patients, 759-762
 percutaneous mechanical thrombectomy for AV fistula salvage, 4:A1, 4:A9
 of SEP, 456-460
 vasectomy as risk factor for urolithiasis, 207-213
see also Percutaneous transluminal renal angioplasty
- Survival, *see* Patient survival; Renal allograft survival; Renal survival in IgAN
- Symptom(s), 671-673
 intradialytic, Na ramping and, 671-672
 postdialytic, Na ramping and, 672, 673
 uremic, correlated with quality of life, 888-896
see also Clinical features and presentation and specific conditions
- Symptom Checklist-90R (SCL-90R) used in MDRD study of CRF patients, 888-896
- Syncope with primary amyloidosis, 4:A3, 4:A18
- Systemic entomophthoromycosis, severe hypertension secondary to, 620-623
- Systemic lupus erythematosus (SLE)
 development of, 14 years after start of HD for ESRD, 631-632
 familial clustering of ESRD in African Americans with, 729-732
 with membranous GN and uterine vasculitis, 277-279
 pediatric, aPLs in, 355-361
see also Lupus nephritis
- Systemic thrombolytic therapy of proteinuria secondary to bilateral renal vein thrombosis, 615-619
- Systolic blood pressure, *see* Blood pressure
- Table salt (sodium chloride), influence of, on antiproteinuric effects of Ca channel blockers, 800-805
- Tacrolimus, *see* FK-506

- Taurine in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446
- Taxol (paclitaxel), effects of, on progression of PKD, 435-444
- Tea polyphenols, anti-oxygen free radicals of, for CRF, 4:A3, 4:A7
- Testosterone, sex and effects of, on progression of ADPKD, 265-272
- TG(s), *see* Triglyceride(s)
- TGF- β , *see* Transforming growth factor- β
- Therapy and management
- of ANCA-associated vasculitis, 97
 - antibiotic, *see* Antibiotics
 - antihypertensive, *see* Antihypertensive therapy
 - anti-oxygen tea polyphenol free radical, for CRF, 4:A3, 4:A7
 - with apheresis, pseudopulmonary embolism in heparin-induced thrombocytopenia and, 449-452
 - of ARF, *see* Acute renal failure, management and outcome of
 - of ascites, 392-398
 - aspirin or ticlopidine, effects of, on platelet deposition on PTFE graft fistulas, 560-564
 - calcitonin, effects of, on low-turnover bone disease in HD patients, 4:A2, 4:A19
 - calcitriol, *see* Calcitriol
 - of chronic metabolic acidosis, 300
 - corticosteroid, *see* Corticosteroids
 - early, of renal disease in diabetic and hypertensive patients, 368-375
 - estrogen replacement, for dialyzed women, 685-690
 - exit-site povidone-iodine ointment, in prevention of PD-related infections, 763-768
 - of fMF with light chain deposition disease, 942-946
 - immunosuppressive, *see* Clinical studies and trials of new immunosuppressive agent(s) and specific immunosuppressive agents
 - α -interferon, of fibrillary GN associated with HCV infection, 132-135
 - of IRD, 179-182
 - lithium, *see* Lithium
 - lupus nephritis, 193-199
 - MMC, endotheliopathy as continuum of HUS due to, 280-284
 - multidisciplinary, of predialysis patients, 533-540
 - nifedipine, effects of discontinuation of, on cytosolic Ca, and B cell proliferation in CRF patients on HD, 233-238
 - nonpharmacological, renal work notion and introduction of, 777-780
 - nutritional, *see* Chronic renal failure, nutrition in; Supplementation; Therapy and management of Fe in CRF and/or ESRD patients on HD and on rHuEPO therapy
 - entries beginning with terms:* Dietary, Parenteral
 - oral glyburide, in NIDDM patients with and without ESRD, pharmacokinetics of, 907-911
 - paclitaxel, effects of, on progression of PKD, 435-444
 - of proteinuric GN, 33
 - RenaGel, *see* RenaGel
 - renal replacement, *see* Renal replacement therapy
 - of severe hypocalcemia, 761-762
 - surgical, *see* Surgery
 - systemic thrombolytic, of proteinuria secondary to bilateral renal vein thrombosis, 615-619
 - of *Xanthomonas maltophilia* peritonitis, 92, 93
 - see also* Ca and phosphate metabolism management in CRF and/or ESRD and specific conditions
- Therapy and management of Fe in CRF and/or ESRD patients on HD and on rHuEPO therapy
- and Fe saturation after initiation or cessation of rHuEPO, 4:A1, 4:A10
 - with oral iron, 325-326
 - with parenteral iron, 326-329
 - strategies for, 329-330
- Three-needle recirculation method, defined, 488
- Threonine in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446
- Thrombectomy, percutaneous mechanical, AV fistula salvage with, 4:A1, 4:A9
- Thrombocytopenia, heparin-induced, pseudopulmonary embolism and, 449-452
- Thrombolytic therapy, systemic, of proteinuria secondary to bilateral renal vein thrombosis, 615-619
- Thrombosis
- heparin-induced, pseudopulmonary embolism and, 449-452
 - with pediatric SLE, aPLs and, 355-361
 - proteinuria secondary to bilateral renal vein, systemic thrombolytic therapy of, 615-619
- Thyroid cancer in renal transplant recipients, 4:A4, 4:A14
- Ticlopidine, effects of, on platelet deposition on PTFE graft fistulas, 560-564
- Time on CAPD and/or HD, 578
- and Ab response to HBV vaccine, 240
 - CRP, rHuEPO resistance and, 566
 - development of SLE 14 years after commencing HD, 631-632
 - effects of, on peritoneal transport, 702
 - nifedipine therapy and, 234
- Time on dialysis
- and attitudes toward financial incentives for kidney donation, 412
 - of ESRD women, reproductive and gynecologic issues and, 686
 - for HCV-positive ESRD, 610, 611
 - of inner-city renal transplant recipients, 883
 - see also* Time on CAPD and/or HD
- Tissue inhibitor of metalloproteinase-1 (TIMP-1) mRNA (messenger ribonucleic acid) in skin fibroblasts of IDDM nephropathy patients, 4:A4, 4:A20
- TNF- α (tumor necrosis factor- α), and Lp effects on mesangial cell proliferation, 925-926
- Tone, MC, effects of disease on, GFR regulation and, 976-977
- Total Ca (calcium)
- effects of P-enriched conventional Ca-containing dialysis solution on, 289
 - serum, in long-term renal transplant recipients, 747, 749
- Total cholesterol in diabetic renal transplant candidates, 602
- Total CO₂ (carbon dioxide) in ARF due to postinfectious nephritis in pregnancy, 274

- Total proteins
 plasma, in IgAN, 530
 postural hemodilution in nephrotic edema and, 628
- Toxic acute renal failure, *see* Oxidants in toxic ARF
- Toxin-related renal injury, ETs in, 12-14
- Training
 future nephrologist, 633-636
see also Education
- Transaminase, *see* Alanine transaminase; Aspartate transaminase
- Transferrin in CRF and/or ESRD
 saturation of, 323-324
 screening for concentrations of, prior to starting patients on rHuEPO therapy, 652
 serum, in patients on HD, rHuEPO resistance and, 567
- Transferrin receptor, soluble, in ESRD, 325
- Transforming growth factor- β (TGF- β)
 in diabetic nephropathy, 153-163
 lisinopril effects on, in membranous nephropathy, 254-264
 and Lp effects on mesangial cell proliferation, 925
- Transitional cell carcinoma in renal transplant recipients, 4:A4, 4:A15
- Transluminal renal angioplasty, *see* Percutaneous transluminal renal angioplasty
- Transpeptidase, gamma-glutamyl, in HCV-positive ESRD patients, 610, 611
- Transplantation, *see* Renal transplantation
- Triglyceride(s) (TGs)
 in CRF, 57, 60
 in diabetic renal transplant candidates, 602
 SLC, albuminuria and, 49, 50
- Triglyceride-rich lipoproteins (TG Lps), effects of, on mesangial cell proliferation, 919-930
- Trimethoprim-sulfamethoxazole, hyperkalemia and, 959-965
- Troponin I and troponin T, serum cardiac, and prognosis of chronic HD patients, 399-403
- Tubular acid secretion in chronic metabolic acidosis, 294-296
- Tubular acidosis
 classification of, 136-146
 and nonacidotic proximal tubulopathy with hypercalciuria, 493
- Tubular cells, proximal, isoflurane effects on energetics of, 4:A1, 4:A12
- Tubular cysts due to chronic lithium ingestion, 4:A3, 4:A5
- Tubular growth in chronic metabolic acidosis, 296-297
- Tubular necrosis, acute, acute allograft rejection and, and IL-8 expression following renal transplantation, 871-880
- Tubular (low molecular weight) proteins in GN with proteinuria, clinical significance and prognostic value of, 27-35
- Tubules
 ETs in, 7-11
 proximal, *see* Proximal tubules
see also entries beginning with term: Tubular and element: Tubulo-
- Tubulointerstitial damage in proteinuric GN, 30, 31
- Tubulopathy, nonacidotic proximal autosomal dominant, 490-495
- Tumor necrosis factor- α (TNF- α), and Lp effects on mesangial cell proliferation, 925-926
- Tunnel infections, catheter with, removal and replacement of, 706-711
- Tunnelled permanent venous catheters for long-term HD vascular access, 4:A2, 4:A16
- Twins, identical, idiopathic membranous nephropathy in, 115-118
- Two-needle recirculation method, defined, 488
- Type I diabetes mellitus (insulin-dependent diabetes mellitus), *see* Diabetes mellitus
- Type I primary hyperoxaluria (PH1), vertical pattern of inheritance of, 36-44
- Type II diabetes mellitus (non-insulin-dependent diabetes mellitus), *see* Diabetes mellitus
- Tyrosine in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446
- Ultrasound, renal, for elevated serum creatinine level, 362-367
- Unemployment among inner-city renal transplant recipients, 881-887
- Unilateral focal segmental glomerulosclerosis (FSGS), RAS and, 936-941
- Universal eating monitor (VIKTOR), eating behavior changes in ESRD patients on CAPD and after renal transplantation monitored with, 691-698
- Upper extremity, pulse oxymetry of O₂ saturation in, with AV fistula before and after HD, pulse oxymetry of, 230-232
- Urea
 blood, and vascular access BF, 224
 clearance of, *see* Urea clearance on CAPD for ESRD
 Na ramping and reduction of, 671
 sampling of, to measure vascular access recirculation in HD of ARF, 4:A1, 4:A10-A11
see also Urea reduction ratio
- Urea clearance on CAPD for ESRD
 before and after CAPD, 695
 cellulose acetate versus PS dialyzers and, 581
- Urea nitrogen
 blood, *see* BUN
 following *H pylori* eradication in ESRD patients on dialysis, 87-88
 postural hemodilution in nephrotic edema and, 628
 serum, *see* Serum urea nitrogen
- Urea reduction ratio (URR)
 with HD of CRF and/or ESRD, *see* Urea reduction ratio with HD of CRF and/or ESRD
 with peripheral AV versus CVV dialysis access, 487-488
see also Kt/V
- Urea reduction ratio (URR) with HD of CRF and/or ESRD and HIVAN, 549-552
 of hyperparathyroidic ESRD, 864
 improvement in, with in-center HD (1993-1995), 851-861
 rHuEPO resistance and, 567
- Uremia
 effectiveness of renal ultrasound for elevated serum creatinine in, 362-367
see also Chronic renal failure; End-stage renal disease; Hemolytic uremic syndrome

- Uremic symptoms in CRF correlated with quality of life, 888-896
- Uric acid
- in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446
 - in hypokalemic metabolic alkalosis with hypomagnesuric hypermagnesemia and severe hypocalciuria, 108
 - in preeclampsia, 347
 - serum, in ARF due to postinfectious GN during pregnancy, 274
- Urinary excretion
- amino acid, in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446
 - in CRF and/or ESRD, *see* Urinary excretion in CRF and/or ESRD
 - K and Cr, in ascitic patients, 394
 - Na, *see* Urinary excretion, Na
 - protein, *see* Urinary excretion, protein
 - see also* Urinary excretion in tubular acidosis and entries ending with suffix: -uria
- Urinary excretion, Na
- in ARF due to postinfectious nephritis in pregnancy, 274
 - ascites and, 394
- Urinary excretion, protein
- in ICGN with HIV and HCV infections, 516
 - in IgAN, 833
 - by membranous nephropathy subjects on lisinopril therapy, 257
 - in SLE, 357
 - see also* Proteinuria
- Urinary excretion in CRF and/or ESRD
- Ca, 643
 - nitrate, ketoconazole plus low-dose prednisone effects on, 503-513
 - P, in secondary HPT with CRF, 499
- Urinary excretion in tubular acidosis, 137-141
- citrate and anion, 140, 141
 - HCO₃, 137-138, 141, 144
 - NH₄, 139-141
- Urinary pH in tubular acidosis, 139, 141
- Urine
- alkaline, PCO₂ in, in tubular acidosis, 138-139
 - analysis of, of high-school students', 4:A2, 4:A15
 - see also* entries beginning with term: Urinary
- Urine volume in ascitic patients, 394
- Urolithiasis
- in PH1, 36-44
 - vasectomy as risk factor for, 207-213
- URR, *see* Urea reduction ratio
- Uterine vasculitis with SLE and membranous GN, 277-279
- Vaccine, HBV, factors influencing Ab response to, in HD patients, 239-245
- Valine in hyperphosphaturia and hypophosphatemia with multiple myeloma, 446
- Varices, bleeding esophageal, portal hypertension and, due to ADPKD, 4:A3, 4:A18
- Vascular access
- computerized communication in management of, 4:A2, 4:A18-A19
 - see also* Blood flow, vascular access; Peripheral arteriovenous versus central venovenous vascular access; Recirculation, vascular access; Vascular access for HD
- Vascular access for HD, 553-559
- of ARF, urea sampling measuring access recirculation and, 4:A1, 4:A10-A11
 - of ESRD with HiVAN, 549-552
 - long-term, *see* Long-term vascular access for HD, catheters for
- Vascular complications, atherosclerotic, in diabetic renal transplant candidates, 601-607
- Vascular disease, chronic, GGS with, in FSGS with NS, 339
- Vascular resistance, renal, chronic lisinopril and/or fosinopril effects on, 901
- Vasculature, *see* Renal vasculature, ET-1 in
- Vasculitis
- ANCA-associated, following renal transplantation, outcome of, 96-102
 - uterine, with SLE and membranous GN, 277-279
- Vasectomy, as risk factor for urolithiasis, 207-213
- Vasoactive agents, GFR regulation by, 972-973
- Venous catheters
- central, paradoxical cerebral air embolism due to, 453-455
 - femoral, recirculation with, 480
 - tunnelled permanent, for long-term HD vascular access, 4:A2, 4:A16
- Venovenous access, *see* Peripheral arteriovenous versus central venovenous vascular access
- Venovenous disequilibrium in peripheral AV versus CVV access
- defined, 488
 - in regional blood flow model, 484-486
- Ventricular hypertrophy, left, and rHuEPO for predialysis CRF patients, 541-548
- Vertical (pseudodominant) pattern of inheritance in PH1, 36-44
- Very-low-density lipoprotein(s) (VLDLs), effects of, on mesangial cell proliferation, 919-930
- Very-low-density lipoprotein-cholesterol (VLDL-C) in CRF, 57
- VIKTOR (universal eating monitor), eating behavior changes in ESRD patients on CAPD and after renal transplantation monitored with, 691-698
- Vitamin B₁₂, screening for, prior to starting rHuEPO therapy of ESRD patients, 652
- Vitamin D for HPT in HD patients, 863
- VLDL(s) (very-low-density lipoproteins), effects of, on mesangial cell proliferation, 919-930
- VLDL-C (very-low-density lipoprotein-cholesterol) in CRF, 57
- Volume loss, compartmental, during HD, 4:A1, 4:A11
- WAS (Wiskott-Aldrich syndrome), HSP with IgA abnormalities and IgAN in carrier of, 285-287
- Water intake, historical notion of, as nonpharmacological therapy, 777-780
- WBCs, *see* White blood cell count and specific white blood cells
- Weight
- kidney, in ADPKD, 267-268

- see also* Body weight
- Weight gain, Na ramping in HD and, 671-673
- White Americans, *see* Race and ethnicity
- White blood cell (WBC) count
- in ARF due to postinfectious GN during pregnancy, 274
- in ESRD with HIVAN, 551
- White matter, felodipine for hypertension with multi-infarct disease, impaired cognitive function, and MRI evidence of, 4:A2, 4:A9
- Wiskott-Aldrich syndrome (WAS), HSP with IgA abnormalities and IgAN in carrier of, 285-287
- Withdrawal from chronic HD, 4:A2, 4:A20
- Women
- African American, diabetic nephropathy and risk of ESRD in, 4:A3, 4:A19-A20
- dialyzed, reproductive and gynecologic issues in, 685-690
- see also* Sex and specific conditions
- Xanthomonas maltophilia* (*X maltophilia*) peritonitis in CAPD patients, 91-95
- Young African Americans, SLC associated with insulin resistance and albuminuria in, 45-53
- Zinc protoporphyrin (ZPP) in ESRD, 325

